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Abstract
ELEVATING ENDOGENOUS CANNABINOIDS REDUCES OPIOID WITHDRAWAL
IN MICE
By Divya Ramesh
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University.
Director: Dr. Aron Lichtman, Ph.D., Professor, Department of Pharmacology & Toxicology
Virginia Commonwealth University
Richmond, Virginia


9-tetrahydrocannbinol (THC), the primary active constituent of Cannabis sativa, has
long been known to reduce opioid withdrawal symptoms. Although THC produces most of its
pharmacological actions through the activation of CB1 and CB2 cannabinoid receptors, the role
these receptors play in reducing opioid withdrawal symptoms remains unknown. The
endogenous

cannabinoids,

N-arachidonoylethanolamine

(anandamide;

AEA)

and

2-

arachidonylglycerol (2-AG), activate both cannabinoid receptors, but are rapidly metabolized by
fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively. The
objective of this dissertation was to test whether increasing AEA or 2-AG, via inhibition of their
respective hydrolytic enzymes, reduces morphine withdrawal symptoms in in vivo and in vitro
models of opiate dependence. Morphine-dependent ICR mice subjected to acute naloxone
challenge or abrupt withdrawal (via pellet removal) reliably displayed a profound withdrawal
syndrome, consisting of jumping, paw tremors, head shakes, diarrhea, and weight loss. THC
and the MAGL inhibitor, JZL184 dose-dependently reduced the intensity of precipitated
withdrawal measures through the activation of CB1 receptors. The FAAH inhibitor, PF-3845,
reduced the intensity of a subset of precipitated signs through the activation of CB1 receptors,
xiv

but did not ameliorate the incidence of diarrhea or weight loss. In the next set of experiments,
MAGL inhibition dose-dependently reduced the intensity of all spontaneous withdrawal signs
(i.e jumps, paw flutters, head shakes, weight loss and diarrhea) in a CB1 receptor dependent
manner. However, FAAH inhibition reduced the intensity of head shakes and paw flutters, but
did not affect other signs. Strikingly, a combination of low-dose JZL184 and high-dose PF-3845
reduced abrupt withdrawal signs in a manner similar to complete MAGL inhibition, which
suggests potential therapeutic advantages of dual enzyme inhibition. This combination elevated
appropriate eCB levels and caused moderate CB 1 receptor desensitization, but did not affect
receptor number in whole brain. Since MAGL, but not FAAH inhibition, blocked diarrhea
during opioid withdrawal in vivo, we investigated whether inhibitors of each enzyme would
differentially attenuate naloxone-precipitated contractions and secretion in morphine-dependent
ilea in vitro. Both enzyme inhibitors attenuated the intensity of naloxone-induced contractions,
and blocked naloxone-precipitated hypersecretion. Although these models offer useful tools for
investigating in vitro end-points of withdrawal, further research is needed to elucidate the antidiarrheal mechanism of these inhibitors. If targeting endocannabinoid catabolic enzymes is
indeed a viable approach to treat other abuse disorders, it is important to know whether these
inhibitors would themselves have abuse or dependence liability. In the final series of
experiments we tested whether prolonged elevation of endocannabinoid leads to the
development of cannabinoid dependence, based on the occurrence of somatic withdrawal signs
upon challenge with rimonabant, a CB1 receptor antagonist. Repeated treatment with high
doses, but not low doses, of JZL184 led to cannabinoid dependence. These results indicate that
the strategy of increasing endogenous cannabinoids through the inhibition of their catabolic
enzymes represents a promising approach to ameliorate opioid withdrawal symptoms.
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Chapter 1: Introduction
Opiate Dependence
Opioids have been used for centuries for their acute analgesic, antitussive, antidiarrheal
and euphoric effects. Importantly, opiates are the mainstay in the management of chronic pain
conditions. Tolerance manifests clinically as the need for increasing drug doses over time to
produce equivalent therapeutic effects and is demonstrated in the laboratory as decreased
potency and/or efficacy of a drug to produce its acute pharmacological effects. Dependence is
revealed upon cessation of opioid treatment and presents as a withdrawal syndrome that
includes both physiological and motivational signs. The risk of opiate dependence from chronic
use of prescription analgesics and illicit substances remains high, despite growing awareness of
the potential for abuse and/or misuse.

An important component of opiate dependence is

withdrawal, an aversive syndrome that occurs on cessation of drug use and contributes to drug
maintenance; thus thwarting efforts for rehabilitation. In humans, spontaneous opioid
withdrawal occurs soon after the last drug use and is characterized by a range of aversive
effects, including behavioral (e.g., anxiety, shakes), gastrointestinal (e.g., diarrhea, emesis,
dehydration), and other physiological effects (e.g., hypertension, tachycardia, and body aches)
(DSM-IV).

Current treatment for opiate withdrawal includes maintenance therapy with

replacement opiates, such as methadone or buprenorphine. However, these opioid agonists also
generate physical dependence. For example, abrupt discontinuation from methadone can trigger
a withdrawal syndrome albeit less severe, but longer lasting than that resulting from heroin
(Dyer et al., 1999).

Similarly, physical dependence has been reported after chronic

buprenorphine treatment (Kuhlman et al., 1998).
1

Given the limitations of these extant

replacement therapies, there is need for non-opioid drug therapies with reduced associated
addiction potential.
Natural Opiates and Opioid Receptors
The naturally occurring opiates such as morphine and codeine are obtained from the poppy
plant Papaver somniferum. The endogenous opioid system consists of several families of
related neuropeptides and the three primary opioid receptor subtypes mu, delta and kappa. The
opioid peptides as well as natural and synthetic opioids act via interactions with these receptors
(Akil et al., 1984; Thompson et al., 1993; Mansour et al., 1995). Opioid receptors were first
identified in 1973 using stereospecific radioligand binding (Pert and Snyder, 1973; Simon et al.,
1973; Terenius, 1973) and subsequently classified into three types, mu, delta and kappa, based
on results of behavioral and bioassay studies (Martin et al., 1976; Lord et al., 1977). Further
pharmacological characterization has revealed that mu opioid receptors mediate the effects of
most clinically relevant opioids, such as morphine and heroin. Cloning of the opioid receptors
confirmed the existence of mu (MOR), kappa (KOR) and delta (DOR) opioid receptors and
confirmed their heptahelical structure (Evans et al., 1992; Kieffer et al., 1992; Chen et al.,
1993a; Chen et al., 1993b; Meng et al., 1993; Thompson et al., 1993). The generation of
genetically altered (transgenic) mice lacking each of the opioid receptors has confirmed that
MOR mediates the acute effects of most clinically relevant opioid drugs, such as analgesia,
respiratory depression, locomotor stimulation and reinforcement, as well as chronic effects such
as physiological withdrawal signs (Matthes et al., 1996; Sora et al., 1997; Loh et al., 1998;
Becker et al., 2000). Heroin, a derivative of morphine, which is rapidly metabolized to 6-acetyl
morphine and subsequently converted morphine, also acts primarily via MOR (Kitanaka et al.,
1998; Contarino et al., 2002).
2

Opioid Withdrawal
Dependence has been defined in DSM-IV as a maladaptive pattern of substance abuse
including tolerance, withdrawal and a persistence desire to take the drug. Chronic use of opiates
such as morphine and heroin leads to tolerance and dependence. Opiate drug abuse affects about
0.6% of the US population annually (NSDUH) and repeated use of opiates leads to abstinence
signs in addicts.
In the preclinical setting the opiate withdrawal syndrome is well characterized in
rodents. Both the precipitated and spontaneous withdrawal model are commonly used to study
opiate abstinence signs. Mice implanted with either a subcutaneous morphine pellet or exposed
to repeated injections of increasing doses of morphine over a period of few days express overt
quantifiable withdrawal signs upon administration of an opiate receptor antagonist, such as
naloxone or abrupt cessation of morphine treatment (Way et al., 1969). The most commonly
observed signs are jumps, paw tremors, head shakes, ptosis, teeth chattering, weight loss, and
production of diarrhea.
Neuroadaptive changes
The most prominent neuroadaptive changes during morphine induced dependence include
desensitization of MORs and upregulation of the cAMP pathway. The mitogen activated protein
kinase (MAPK) pathway as well as Ca2+ signaling are also affected during morphine
dependence with MAPK levels being modulated differentially by morphine treatment in
different parts of the brain. The primary consequence of morphine withdrawal is
‘superactivation’ of adenylyl cyclase (AC) and a subsequent overproduction of its downstream
signaling molecule, cAMP. MOR signal transduction is Gα

3

i/o

coupled and chronic stimulation

of µOR by morphine leads to suppression of AC activity over a prolonged period of time.
Concurrently, chronic morphine treatment also causes compensatory increases in activity of
other subforms of AC thus restoring cAMP levels back to normal over the time course of
chronic morphine treatment. When morphine treatment is abruptly halted or an opiate receptor
antagonist such as naloxone is administered, causing disinhibition of AC activity and leading to
massive overstimulation of AC coupled with increased AC production. This process leads to an
overactivation of other downstream effectors of AC such as cAMP, PKA and transcription
factors such as cAMP response element binding protein (CREB) (Nestler and Tallman, 1988;
Guitart et al., 1992) (Fig. 1). CREB is also a downstream target of MAPK and Ca2+ (Eitan et al.,
2003). Other cAMP actions during withdrawal include PKA-mediated enhanced GABAergic
synaptic transmission in areas such as periaqueductal grey (PAG), ventral tegmental area
(VTA), nucleus accumbens (N Acc.) and dorsal raphe. [For complete review see (Williams et
al., 2001; Bailey and Connor, 2005; Sim-Selley, 2005)]

Figure 1: Effects of acute and repeated exposure to opiates
(Rt-left) Chronic morphine exposure leads to upregulation of AC and normalization of
downstream signaling; Induction of withdrawal following chronic morphine exposure causes
cAMP “overshoot” and increasing signaling of cAMP cascade resulting in expression of
withdrawal signs
4

The cAMP superactivation and changes in CREB activation during withdrawal is most
prominent in the LC as well as in N Acc, amygdala, DRN and VTA and is associated with the
expression of external somatic signs during withdrawal (Widnell et al., 1994; Lane-Ladd et al.,
1997; Shaw-Lutchman et al., 2002; Han et al., 2006). CREB mediates the action of opioids on
the expression of several genes in brain regions responsible for drug-seeking behavior and
manifestation of withdrawal mediated changes in synaptic plasticity (Bilecki and Przewlocki,
2000). CREB binds to cAMP response element (CRE) in the promoter region of target genes
and enhances the transcription of these genes. The phosphorylation of CREB is determined by
cAMP in the LC and its function is regulated by the MOR. Further evidence for a role of CREB
in mediating cellular adaptation in response to chronic opioid treatment is that LC neurons show
decreased hyperexcitability following morphine withdrawal in CREB1(-/-) mice and in mice
with a conditional mutation in CREB (Valverde et al., 2004). It is likely that adaptations to
MORs in this brainstem region contribute to dependence and withdrawal.
Cannabinoids
Marijuana or Cannabis sativa has been used and cultivated for a variety of purposes as
archaeological evidence dates back to 2350 B.C (Cannabinoids in nature and medicine, 2009).
Δ9-tetrahydrocannabinol (THC) is the primary psychoactive constituent of marijuana. In
addition, more than 70 other phytocannabinoids have been discovered (Elsohly and Slade,
2005), and hundreds, if not thousands, of cannabinoids have been synthesized. The first
constituent of marijuana was isolated by Roger Adams in 1940; which came to known as
cannabidiol, lacking psychoactive properties and whose structure was later completely
determined by Raphael Mechoulam (Adams et al., 1940; Mechoulam and Gaoni, 1965). In
1964, Raphael Mechoulam was the first to report on chemical compounds extracted and isolated
5

from cannabis sativa which contributed to the biological activity of the plant. While discovering
several active compounds of similar lipid structural class, he isolated Δ 9-tetrahydrocannabinol
(THC) as the primary psychoactive compound responsible for marijuana’s activity (Gaoni and
Mechoulam, 1964). The FDA has since approved Marinol® (synthetic THC) for the treatment of
AIDS related anorexia and emesis induced by chemotherapy. In Canada and Europe, Sativex ®
(THC:cannabidiol; 1:1) is approved for the management of cancer pain and neuropathic pain
associated with multiple sclerosis. However, marijuana and THC have several non-approved
beneficial applications such as anxiolysis, management of chronic pain and treatment of abuse
disorders. However, dependence, particularly withdrawal from prolonged cannabinoid use,
which limits clinical utility of cannabis and its psychoactive ingredients as well as direct acting
CB1 receptor agonists.
Cannabinoid dependence
Studies of cannabis dependence and withdrawal in humans
While classical cannabinoids such as THC have many promising clinical applications,
including the treatment of opiate dependence, the therapeutic potential of marijuana as well as
THC is limited by their dependence liability. While the current revisions of the DSM-IV and
ICD-10, the two most common diagnostic guidebooks used by medical professionals today to
diagnose substance-use disorders, include criteria and symptomology for diagnosing cannabis
abuse and dependence, only the latter recognizes a withdrawal syndrome as a component of a
cannabis dependence disorder (American Psychiatric and American Psychiatric Association.
Task Force on, 2000). The DSM-IV reflects a common attitude of many in medicine and the
general public that cannabis is not a physically addictive substance in which a withdrawal
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syndrome can produce clinically relevant symptoms of any severity and duration to impact
subsequent substance-use behavior. The source of this belief is likely due to a multitude of
factors, such as the relatively slow onset and unique constellation of the withdrawal syndrome,
and is further described below.
Cannabis is the most commonly used illicit drug worldwide, with approximately 56% of
young adults (i.e., 19-28 years) in America having tried cannabis in their lifetime (Johnston,
2010) . This high prevalence of marijuana use allows for many people to have personal and/or
anecdotal experience with marijuana without necessarily having personal interactions with
dependent users. So while only about 3-4% of individuals who have ever tried cannabis meet
criteria for a cannabis-use disorder (compared with 15-25% for cocaine), the total number of
Americans classified with such disorders is 4.3 million, more than twice that of cocaine and
heroin combined (SAMHSA and Studies, 2008). In addition, the severity of cannabis
withdrawal is not generally associated with any symptoms requiring hospitalization or viewed
as potentially life-threatening (Wallace and Cunningham, 1944). Furthermore, only a subset of
regular marijuana users experience a clustering of symptoms upon cessation of use, with reports
of frequency ranging from 1/6 up to 1/2 (Wiesbeck et al., 1996; Budney et al., 1999). Common
symptoms observed during cannabis withdrawal include anger, aggression, irritability,
anxiety/nervousness, decreased appetite or weight loss, restlessness, and sleep difficulties with
strange dreams (Budney and Hughes, 2006). Marijuana withdrawal has been compared to that
of tobacco, and is reported to increase craving and desire to resume use (Budney et al., 2008;
Vandrey et al., 2008). A similar abstinence syndrome has also been shown upon cessation of
repeated oral THC, the primary psychoactive component of marijuana, in human studies (Haney
et al., 1999). While the immediate physical impact of these symptoms are mild when compared
7

to certain other drugs of abuse the comprehensive impact of the cannabis withdrawal syndrome
is becoming better understood. However, any abstinence syndrome may increase the desire to
continue drug use and thus, represents a complication in treating dependence from other drugs
of abuse.[For a complete review see (Ramesh et al., 2011b)]
Neurobiological adaptations during cannabinoid dependence
In addition to the increased characterization of a behavioral profile during cannabinoid
withdrawal, preclinical studies have investigated the molecular changes that result from
repeated exposure, and cessation, of cannabinoids. Such studies provide indicators of
adaptations that drive withdrawal symptomology, and improve strategic targeting of
therapeutics. Chronic administration of cannabinoid agonists results in down-regulation of the
CB1 receptor in several brain regions (e.g., cerebellum, hippocampus and striatum with globus
pallidus) as measured by radioligand binding (Breivogel et al., 1999). At the level of the Gprotein, chronic treatment with THC produces a time and region-dependent desensitization of
CB1 receptor activity (Romero et al., 1997; Breivogel et al., 1999). Other evidence of
dysregulation within the endocannabinoid system includes region-specific alterations in
endocannabinoid content following precipitated withdrawal in rats and mice in the cerebellum,
cortex, limbic forebrain and brainstem (Gonzalez et al., 2004).
Alterations in numerous other neurotransmitter systems are also associated with
withdrawal from THC in rodents. Following chronic administration of THC, brain levels of
serotonin are decreased, concurrent with increases in its primary metabolite (Taylor and
Fennessy, 1978; Taylor and Fennessy, 1982).

The finding that various serotonin uptake

inhibitors elicited writhing behavior, backward kicks, jumps, and wet shakes in rats treated
repeatedly with THC, suggests serotonergic involvement in cannabinoid withdrawal-like
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behavior (Verberne et al., 1980). In addition, histamine levels in the brain decrease both during
initial exposure to THC, as well as during somatic withdrawal induced by a serotonin reuptake
inhibitor clomipramine (Verberne et al., 1985).

Several studies have shown evidence of

upregulation and release of the stress-related peptide corticotropin-releasing factor upon
precipitated withdrawal, a phenomenon common during withdrawal to many drugs of abuse
(Rodriguez de Fonseca et al., 1997; Gonzalez et al., 2004).
At the intracellular level, the cAMP second messenger signaling system appears to
modulate cannabinoid withdrawal. Rimonabant administered to THC-dependent mice resulted
in significant increases in both basal and forskolin-stimulated adenylyl cyclase activity in the
mouse cerebellum, but not in other regions (Hutcheson et al., 1998). Similar results were
obtained with calcium-calmodulin stimulated cyclase activity from cerebella of THC-dependent
rats undergoing precipitated withdrawal (Rubino et al., 2000). Rimonabant-precipitated
cannabinoid withdrawal also results in upregulation of protein kinase A (PKA) activity, which
is downstream of cAMP, in the cerebella of THC dependent rats (Tzavara et al., 2000).
Additionally, infusions of the cAMP blocker Rp-8Br-cAMPs into the cerebellum attenuated
expression of precipitated withdrawal signs and PKA activity in rats undergoing precipitated
withdrawal. Conversely, infusion of Sp-8Br-cAMPs, a cAMP analog, into the cerebellum
elicited cannabinoid withdrawal somatic signs in drug naïve mice. These findings provide
strong evidence for the functional role of the cAMP cascade, particularly in the cerebellum, in
modulating withdrawal from cannabinoids.
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The endocannabinoid system
Cannabinoid receptors
THC, as well as many other cannabinoids, has been demonstrated to bind to and activate
two types of cannabinoid receptors that have been cloned, CB 1 (Matsuda et al., 1990) and CB2
(Gerard et al., 1991). Both cannabinoid receptors are G-protein coupled receptors, which are
associated with Gi/o G-proteins [for a complete review see (Howlett, 2002)]. Activation of these
receptors decreases cAMP production via blockade of adenylyl cyclase (Howlett et al., 1990),
activation of inwardly rectifying potassium (GIRK) channels via Gβγ subunits (Mackie et al.,
1995; McAllister et al., 1999). Furthermore activation of the cannabinoid receptors inhibits Nand P/Q-type calcium channels, which reduces synaptic vesicle fusion to the nerve terminal
thereby inhibiting the release of excitatory and inhibitory neurotransmitters. The CB1 receptor is
heterogeneously expressed throughout the central nervous system (CNS) and periphery
(Herkenham et al., 1990; Matsuda et al., 1993; Felder and Glass, 1998) and has been
demonstrated to be responsible for most of the pharmacological actions of THC, particularly
within the CNS. In support of this notion, cannabinoids induce tetrad effects (decrease in
locomotor activity, hypothermia, catalepsy, and analgesia) which are reversed by a CB1
antagonist and do not occur in CB1 (-/-) mice (Rinaldi-Carmona et al., 1994; Compton et al.,
1996b). The CB2 receptor is tightly associated with immune cells (Klein et al., 2003) and was
initially believed to be expressed solely in the periphery. However, more recently this receptor
has been found to be expressed in microglial cells (Cabral and Marciano-Cabral, 2005) and in
neurons (Van Sickle et al., 2005) within the brain. CB1 and CB2 receptors share approximately
44% homology with each other (Munro et al., 1993). Cannabinoid receptors have been localized
on presynaptic terminals of both GABAergic (Katona et al., 1999) and glutamatergic neurons
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(Huang et al., 2001; Szabo and Schlicker, 2005). Transient suppression of the inhibitory
transmission (i.e. GABA) is termed depolarization-induced suppression of inhibition (DSI).
Conversely transient suppression of the stimulatory neurotransmitter (e.g. glutamate) is called
depolarized-induced suppression of excitation (DSE). Both result in cannabinoid receptor
mediated hyperpolarization of a repetitively depolarized neuron, which suppresses subsequent
vesicular fusion and release of glutamate or GABA.
Endogenous ligands and their regulatory pathways
A major breakthrough in cannabinoid pharmacology came with the discovery of the
endogenous cannabinoids (endocannabinoids), which activate and bind to cannabinoid receptors
(Di Marzo and Fontana, 1995). These endocannabinoids are derived from phospholipid
precursors in the postsynaptic neuron. Unlike classical neurotransmitters, endocannabinoids are
not stored in vesicles, but are released on demand and travel in a retrograde manner from postsynaptic terminals to act on pre-synaptic cannabinoid receptors (Ahn et al., 2008). The most
noteworthy endocannabinoids discovered are N-arachidonylethanolamine (anandamide, AEA)
(Devane et al., 1992) and 2-arachidonylglycerol (2-AG) (Mechoulam et al., 1995; Sugiura et al.,
1995). Additionally, three other endocannabinoids have been discovered, which include
nolandin ether (Hanus et al., 2001), virodhamine (Porter et al., 2002) and N-arachidonyl
dopamine (Huang et al., 2002). Despite sharing common receptors and considerable structural
similarity, AEA and 2-AG can be distinguished by multiple factors. First, these
endocannabinoids activate cannabinoid receptors to different degrees in vitro, with anandamide
acting as a partial agonist whereas 2-AG acts a full agonist at the CB1 receptor (Gonsiorek et al.,
2000). Mice repeatedly treated with FAAH inhibitors as well as FAAH(-/-) mice show normal
CB1 function and display CB1 desensitization following treatment with exogenous AEA. On the
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other hand, prolonged exposure to the MAGL inhibitor JZL184 as well as MAGL(-/-) results in
significant downregulation and desensitization of CB1 receptors as well as physical cannabinoid
withdrawal (Falenski et al., 2010; Schlosburg et al., 2010). Second, the endogenous quantities
of anandamide and 2-AG differ dramatically, with the latter being found at more than 100-fold
higher concentrations in the nervous system (Ahn et al., 2009; Long et al., 2009a). Third, while
AEA and 2-AG both activate CB1 and CB2, AEA has been has also been shown to activate
vannilloid (TRPV1) and PPARα receptors (Ross, 2003; Jhaveri et al., 2008). Finally, the
available signaling pool for each lipid is regulated by distinct synthetic and catabolic enzymatic
pathways [(Ahn et al., 2008) summarized in Fig 2].
AEA synthesis is regulated by multiple pathways, and was initially believed to be
formed via cleavage of N-arachidonylphosphatidylethanolamine (NAPE) by NAPEphospholipase D. However, it has been shown that NAPE-PLD knock-out mice possess wildtype levels of AEA (Leung et al., 2006) suggesting that the existence of other biosynthetic
pathways. Other pathways of AEA synthesis include via phosphodiesterase (PDE), or synthesis
via cleavage of phospholipase C (PLC) and a phosphatase (Liu et al., 2006). On the other hand,
2-AG is synthesized by the cleavage of diacylglycerol (DAG) by DAG lipase-alpha (DAGLα)
(Gao et al., 2010; Tanimura et al., 2010). This is evidenced by the observation that DAGLα (-/-)
mice when compared to DAGLβ (-/-) mice exhibit a significantly decreased production of 2-AG
levels.
As with most signaling messengers, AEA and 2-AG are rapidly inactivated soon after
they are released. AEA is taken back into the post-synaptic terminal and degraded by the
enzyme fatty acid amide hydrolase (FAAH) (Cravatt et al., 1996). FAAH is located within the
post-synaptic terminal (Gulyas et al., 2004) and is responsible for the degradation of other fatty
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acid amides (FAAs) such as oleamide, the sleep agent, palmitoylethanolamide (PEA), the antiinflammatory agent, and oleylethanolamide (OEA) the satiety lipid (Cravatt et al., 1995).
Conversely, approximately 85% of 2-AG is degraded within the presynaptic terminal by the
enzyme monoacylglycerol lipase (MAGL), while the remaining 2-AG is degraded by enzymes
alpha/beta hydrolase 6 and 12 (ABHD) (Blankman et al., 2007). Although 2-AG is present at
levels 170-1000 fold greater than AEA (Sugiura et al., 2002), both endocannabinoids produce
some similar cannabinoid effects in vitro. Administration of THC or other synthetic
cannabinoids do not elicit effects mimicking the physiological effects of endocannabinoids
because the former causes a persistent inhibition of neurotransmitter release, while the latter
elicits localized and transient effects (Vaughan and Christie, 2005).
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Figure 2. The endocannabinoid system (CNS): receptors, ligands and their regulatory pathways
[Adapted from (Ahn et al., 2008)]
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Inhibitors of endocannabinoid catabolic enzymes: second generation inhibitors
It is noteworthy that blockade of the enzymes fatty acid amide hydrolase (FAAH) and
monoacylglycerol lipase (MAGL) or their genetic deletion elevates brain levels of the
respective endocannabinoids, AEA (Kathuria et al., 2003; Lichtman et al., 2004) and 2-AG
(Long et al., 2009a). FAAH (-/-) mice have been generated by inducing a targeted disruption of
the FAAH gene by removing the first exon of the gene by homologous recombination. These
mice show 10-fold elevations of AEA, other FAAs (e.g., OEA, PEA) in CNS and display an
antinociceptive phenotype (Cravatt et al., 2001). Irreversible (PF-3845, URB597) as well as
reversible inhibitors of FAAH elevate AEA levels multi-fold in the brain (Fegley et al., 2005;
Ahn et al., 2009). Importantly, PF-3845 is highly selective for FAAH, unlike URB597 that also
binds to other serine hydrolases. Acute treatment with PF-3845 results in FAAH inhibition up to
24 h and maximal AEA elevation up to 12 h in mice. In pharmacological assays, PF-3845 has
analgesic effects in the lipopolysaccharide (LPS), chronic constrictive injury (CCI) and acetic
acid stretching models of pain as well as anxiolytic-like effects in marble-burying assay (Kinsey
et al., 2010; Booker et al., 2011; Kinsey et al., 2011b).
Similarly MAGL, the primary degradative enzyme for 2-AG, represents a target for the
development of selective inhibitors to treat pain and inflammatory, anxiety-related, and
cannabis-related and other abuse disorders. Genetic deletion or complete pharmacological
inhibition of MAGL with JZL184 increases brain 2-AG levels by approximately 10-fold (Long
et al., 2009a; Long et al., 2009b; Schlosburg et al., 2010). The pharmacological actions of
JZL184 have been summarized in Table 1. It should be noted that JZL184 can also inhibit
FAAH, though in vitro the compound is approximately 500-fold more selective as a MAGL
inhibitor (IC50 = 8 nM) than as a FAAH inhibitor (IC50 = 4,000 nM) (Long et al., 2009a).
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Although acute administration of 40 mg/kg JZL184 in ethanol:emulphor:saline (1:1:18) vehicle
inhibits FAAH activity by approximately 50%, this inhibition is insufficient to increase brain
AEA levels (Long et al., 2009b).
Table 1. Pharmacological effects of JZL184 in preclinical assays
Species

Type of Assay

Dosing Regimen

Effect
Hypothermia,

Mouse

Tetrad

JZL184 (40 mg/kg,

hypomotility,

acute ;i.p.)

catalepsy, hyperreflexia

JZL184 (8, 16
Mouse

Acetic acid stretching

mg/kg; acute & 8
mg/kg repeated;

JZL184 (16,40

cold allodynia)

mg/kg; acute; i.p.)

Mouse;

Carrageenan-induced

JZL184 (4-40

Rat

paw inflammation

mg/kg; i.p.)

Mouse

Bone cancer pain

Rat
Rat

Formalin pain test

Capsaicin-induced

2009a; Long et
al., 2009b)

Antinociception

2009a; BusquetsGarcia et al.,
2011)

CCI (mechanical &

Mouse;

(Long et al.,

(Long et al.,

i.p.)

Mouse

Reference

JZL184 (10 μg;
i.p.l)

(Kinsey et al.,
Anti-allodynic

2009; Kinsey et
al., 2010)

Partial anti-

(Ghosh et al.,

allodynic and anti-

2012;

edema

unpublished)

Anti-hyperalgesic

(Khasabova et
al., 2011)

JZL184(16 mg/kg

Antinociceptive at

(Long et al.,

i.p.); (0.001-300

both early and late

2009a; Guindon

µg; i.pl)

phase

et al., 2011)

JZL184 (100µg;

Antinociception

(Spradley et al.,
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behavioral

i.pl)

and anti-

sensitization
Mouse

Mouse

Marble burying

Elevated plus-maze;
zero maze

hyperalgesia
JZL184 (16, 40
mg/kg; i.p.)

Elevated plus-maze

acute & repeated;

Mouse

gastric ulcers

Anxiolysis:

i.p.)

mg/kg; acute &
repeated; i.p.)

NSAID induced

Anxiolysis

JZL184 (8 mg/kg;

JZL184 (4- 8
Rat

2010)

JZL184 (4 mg/kg;
acute & repeated;
i.p.)

(Kinsey et al.,
2011b)
(Busquets-Garcia
et al., 2011)

Anxiolysis under

(Sciolino et al.,

high-stress

2011)

Prevents gastric

(Kinsey et al.,

hemorrhage

2011a)

Restoration of
intestinal barrier
Mouse

(TNBS)-induced

JZL184 (16 mg/kg;

integrity;

(Alhouayek et

colitis

i.p.)

inhibition of pro-

al., 2011)

inflammatory
cytokine release
Shrew

Mouse

Mouse

LiCl- induced

JZL184 (16,40

vomiting

mg/kg; i.p.)

THC physical

JZL184 (16 mg/kg;

Attenuation of paw (Schlosburg et

withdrawal

i.p.)

flutters

Opioid withdrawal

JZL184 (4-16
mg/kg; i.p.)
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Anti-emetic

Attenuation of
somatic
withdrawal signs

(Sticht et al.,
2011)

al., 2009)
(Ramesh et al.,
2011a)

DSE from Purkinje
neurons in cerebellar
Mouse;

slices and DSI from

rat

CA1 pyramidal

JZL184 (1µM)

Prolongation of
DSE and DSI

neurons in

(Pan et al., 2009;
Schlosburg et al.,
2010)

hippocampal slices
Aβ induced
Rat

cytotoxicity and IHC
in hippocampal

reduces AβJZL184 (3µM)

neurons

induced

(Chen et al.,

neurodegeneration

2011)

and apoptosis
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Rationale and hypothesis
Overall hypothesis
Inhibition of the endocannabinoid catabolic enzymes FAAH and MAGL will reduce morphine
withdrawal somatic signs and diarrhea in mice through the activation of cannabinoid receptors
by anandamide and 2-AG, respectively.
Selection of MAGL and FAAH inhibitors
We specifically chose the respective irreversible MAGL and FAAH inhibitors, JZL184 and PF3845, since they are amongst the most selective inhibitors presently available (Ahn et al., 2009;
Long et al., 2009b). The inhibitors are highly selective for either enzyme, have a long half-life
(up to 24 h), produce profound (10-fold) elevations of the appropriate endocannabinoid (up to
12 h) and have few off-site targets. It should be noted that JZL184 can also inhibit FAAH,
although in vitro the compound is approximately 500-fold more selective as a MAGL inhibitor
(IC50 = 8 nM) than as a FAAH inhibitor (IC50 = 4,000 nM) (Long et al., 2009a). In vivo, acute
treatment with JZL184 leads to partial FAAH inhibition without elevation of AEA. However,
repeated treatment with JZL184 leads to augmented levels of AEA in mice (Schlosburg et al.,
2010).
Chapter 2. Dependence liability of MAGL and FAAH inhibitors
In initial studies, we examined the dependence liability of FAAH and MAGL inhibitors
in the precipitated cannabinoid withdrawal model. We employed FAAH (-/-) mice, FAAH
inhibitors, and MAGL inhibitors to examine the role of endocannabinoid elevations in
modulating established CB1-mediated responses (see Chapter 2). We expected that mice that
had been subjected to prolonged FAAH inhibition would show no signs of precipitated physical
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withdrawal. This prediction is based on previous studies demonstrating minimal drug abuse
potential and adaptations of cannabinoid receptors following prolonged FAAH inhibition
(Schlosburg et al., 2009; Falenski et al., 2010; Schlosburg et al., 2010). MAGL inhibition may
have a greater potential of physical dependence than FAAH, as 2-AG is a full agonist and its
concentration in brain is approximately 200 fold greater than that of anandamide. Simultaneous
prolonged inhibition of both MAGL and FAAH is expected to lead to cannabinoid dependence,
as dual inhibition acutely has shown numerous characteristics similar to THC not seen under
conditions with either enzyme inhibited alone, notably catalepsy and THC substitution in
discriminative stimulus testing. Finally, we evaluated the abuse liability of partial MAGL
inhibition by using a low dose of JZL184 alone in combination with high dose of the FAAH
inhibitor PF-3845. We predicted that development of cannabinoid dependence from prolonged
MAGL inhibition is dose-dependent with rimonabant precipitating physical withdrawal in mice
treated repeatedly with high doses of JZL184.
Chapter 3. Effects of inhibitors on naloxone-precipitated opioid withdrawal – Somatic signs
In Chapter 3, we described experiments that evaluated whether elevating
endocannabinoids, through the inhibition of their catabolic enzymes, attenuates naloxoneprecipitated withdrawal symptoms in morphine-dependent mice. A growing body of literature
demonstrates that elevating endogenous cannabinoids by inhibiting their hydrolytic enzymes
offers potential therapeutic benefits, without the undesirable cannabimimetic actions of the
exogenous cannabinoids. We investigated the efficacy of these inhibitors to reduce naloxoneprecipitated jumps, paw flutters, diarrhea and weight loss in mice implanted with morphine
pellets. The effects of these enzyme inhibitors were compared to those of THC. Selective CB 1
and CB2 receptor antagonists were employed to assess cannabinoid receptor involvement of the
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anti-withdrawal effects of JZL184 and PF-3845. In order to evaluate whether compensatory
changes of endocannabinoids occur during the state of withdrawal, AEA and 2-AG levels were
quantified in brain regions associated with opioid dependence (i.e., the locus coeruleus (LC),
periaqueductal grey (PAG), and amygdala). We hypothesize that MAGL and FAAH inhibitors
as well as THC will attenuate signs of precipitated opioid withdrawal through the activation of
CB1 receptors. We suggest this hypothesis based on observations that THC and other exogenous
cannabinoid agonists such as AEA and 2-AG have been demonstrated to reduce signs of
naloxone-precipitated withdrawal signs in rodents (Hine et al., 1975; Bhargava, 1976; Vela et
al., 1995; Yamaguchi et al., 2001).
Chapter 4. Effects of MAGL and FAAH inhibitors on spontaneous opioid withdrawal signs
In Chapter 4, we used the spontaneous withdrawal model since it represents high face
validity for withdrawal typically experienced by opioid-dependent individuals. Accordingly, we
investigated the dose response relationship of the MAGL inhibitor JZL184 to reduce
spontaneous withdrawal induced jumps, paw flutters, head shakes, diarrhea and weight loss in
mice implanted with morphine pellets. Next, we tested the effectiveness of a novel combination
of low-dose JZL184 and high dose of the FAAH inhibitor PF-3845 in reducing abrupt morphine
withdrawal signs. This combination was selected in an attempt to produce maximal morphine
anti-withdrawal effects, while minimizing side effects of JZL184 (see Chapter 4). The selective
CB1 receptor antagonist, rimonabant was employed to assess cannabinoid receptor involvement
of the anti-withdrawal effects of JZL184 and the combination. In order to evaluate whether
compensatory changes of endocannabinoid system occurs following treatment with MAGL and
FAAH inhibitors in ICR mice, endocannabinoid and arachidonic acid (AA) levels were
quantified in whole brain. In addition, we measured changes in CB1 receptor binding and G21

protein activation from brains of mice repeatedly treated with MAGL and FAAH inhibitors.
We hypothesize that the combination will also reduce all signs of spontaneous withdrawal
without inducing cannabimimetic behavioral effects and receptor adaptations. We predict these
results based on the observation that the combination produces augmented analgesic efficacy
and lacks dependence potential (Kinsey, Wise et al., unpublished data; Chapter 2 results).
Chapter 5. Anti-diarrheal mechanism of action of MAGL inhibition: In vitro naloxoneprecipitated withdrawal - ileum
Given the differential effects of MAGL and FAAH inhibition on diarrhea during
morphine withdrawal we investigated the effects of JZL184 and PF-3845 on naloxoneprecipitated contractions in vitro in the ileum (Chapter 5). The ileum offers a useful in vitro
model to investigate opioid withdrawal (Paton, 1957). Endocannabinoid catabolic enzyme
inhibitors were also assessed for their efficacy in reducing electric field stimulated (EFS)
contractions in naïve untreated ilea. Since it is known that cannabinoids such as THC and WIN55212 reduce naloxone-precipitated contractions in morphine-treated ilea, we hypothesize that
MAGL and FAAH inhibitors will reduce naloxone-precipitated neurogenic contractions in a
CB1-dependent manner. The precursors for diarrhea include both hyper-contractility as well as
increased secretion of fluids and electrolytes. Hence, we also evaluated whether PF-3845 and
JZL184 inhibit naloxone-precipitated hypersecretion of electrolytes in morphine-treated ileum
in the Ussing’s chamber. To study the involvement of CB1 receptors we investigated the effects
of JZL184 in morphine-treated ilea from CB1(-/-) mice. We hypothesized that both MAGL and
FAAH inhibition will reverse naloxone-precipitated hypersecretion via CB1 mechanism since its
known that cannabinoid agonists have anti-secretory effects in small intestine. To verify that
pharmacological actions of MAGL inhibition are mediated by increases of 2-AG and/or
22

concomitant decreases in arachidonic acid levels, we quantified whether PF-3845 and JZL184
alter endocannabinoids, free arachidonic acid, and prostaglandins in ileum.
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Chapter 2: Evaluation of rimonabant-precipitated withdrawal in mice subjected to
prolonged inhibition of eCB catabolic enzymes
In these experiments, we asked whether prolonged MAGL or FAAH blockade produces
cannabinoid physical dependence, a phenotype that has been observed in rodents that have been
exposed to repeated treatments with direct CB1 agonists.
Preclinical Studies of Cannabinoid Dependence
Repeated administration of THC or other cannabinoid agonists leads to dependence in a
variety of laboratory animals. Preclinical models for assessing dependence include those for
measuring reinforcing and rewarding properties, such as self-administration, conditioned place
preference, and intracranial self-stimulation (for a complete review see Panagis et al., 2008) as
well as withdrawal signs. The withdrawal can include both physiological signs, as well as
indicators of emotional state.
a. Characterization of cannabinoid withdrawal
The two general procedures used to induce a state of drug withdrawal in preclinical drug
dependence studies are spontaneous withdrawal and precipitated withdrawal. Spontaneous
withdrawal occurs following abrupt cessation of the drug, which is metabolized and cleared
from the body. In precipitated withdrawal, an appropriate selective receptor antagonist is used
to displace the agonist from the receptor resulting in the rapid onset of withdrawal symptoms.
The specific withdrawal symptoms, intensity, and duration depend on the pharmacologic
characteristics of the compound, with drugs from the same class generally sharing similar
withdrawal syndromes. The precipitated withdrawal model is employed more often than the
spontaneous withdrawal model to investigate cannabinoid dependence in laboratory animals
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because of the long half-life of THC and subtle withdrawal effects make it difficult to observe
and quantify upon abrupt cessation. The results of preclinical studies employing precipitated
and spontaneous withdrawal procedures are shown in Table 2.
b. Spontaneous Cannabinoid Withdrawal in Laboratory Animals
The quantification of abrupt withdrawal signs in laboratory animals is very challenging as
THC has a long half-life (Huestis, 2005) resulting in delayed onset and longer duration of
withdrawal symptoms. The results from laboratory studies have often been mixed. The study of
somatic withdrawal signs from repeated administration of THC and other cannabinoids has been
examined in different animal species. While a variety of abnormal behavior signs, such as
tremors, wet dog shakes and hyperirritability, have been reported in rats (Kaymakcalan et al.,
1977), other studies failed to find significant abrupt withdrawal signs in rodents (Leite and
Carlini, 1974; Aceto et al., 1996). Similarly, spontaneous withdrawal signs were not observed in
pigeons following chronic exposure to THC (McMillan et al., 1973). Rhesus monkeys
chronically infused with intravenously administered THC (0.5 mg/kg q.i.d. for 3 weeks)
displayed substantial increases in gross movement, eye contact, and tooth baring during the
first week of abstinence (Fredericks and Benowitz, 1980). These behaviors reflect rebound
withdrawal symptoms, as they were initially suppressed by acute THC and subsequently
underwent tolerance. In another study, food reinforced operant responding was decreased in
monkeys following upon abrupt cessation of drug infusions (Beardsley et al., 1986).
Spontaneous withdrawal responses also occur following discontinuation from chronic
administration of the full cannabinoid receptor agonists WIN-55, 212 in rats (Aceto et al., 2001)
and CP-55,940 in mice (Oliva et al., 2003). The data from these studies suggest that while
spontaneous withdrawal from cannabinoids can be observed in experimental animals, the ability
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to observe and quantify these withdrawal effects depends on various factors such as: the
species, cannabinoid selected, duration of drug administration, the time point at which
withdrawal is assessed, and the specific end points. While the spontaneous withdrawal
procedure presents with considerable challenges and may be prone to false negatives because of
the slow elimination of THC and its metabolites (Huestis, 2005), it is considered to possess
more face validity than precipitated withdrawal procedure for modeling human cannabis
withdrawal.
c. Precipitated Cannabinoid Withdrawal in Laboratory Animals
The development of the CB1 receptor antagonist rimonabant (Rinaldi-Carmona et al., 1994)
and other CB1 receptor antagonists has provided highly useful tools to investigate precipitated
withdrawal in cannabinoid-dependent animals. Rimonabant binds with high affinity to the CB 1
receptor and antagonizes the pharmacological effects of many cannabinoid receptor agonist
activities in laboratory animals and humans (Rinaldi-Carmona et al., 1994; Compton et al.,
1996a; Lichtman et al., 1998b; Winsauer et al., 1999; Huestis et al., 2001; Huestis et al., 2007).
Somatic Withdrawal Signs: Soon after the discovery of rimonabant, two separate groups
independently used this antagonist to demonstrate somatic precipitated withdrawal signs in rats.
These withdrawal signs include wet-dog shakes, forepaw fluttering, chewing, increased
horizontal and vertical activity, retropulsion, and ptosis (Aceto et al., 1995; Tsou et al., 1995).
Rimonabant also precipitates a profound withdrawal syndrome in mice that are chronically
exposed to either THC or marijuana smoke (Cook et al., 1998; Wilson et al., 2006). The
withdrawal signs commonly observed in mice, such as paw tremors and wet dog shakes, are
observed consistently across all strains (Cook et al., 1998; Huang et al., 2009). Other signs such
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as mastication, sniffing, and pilerection are of low frequency, but are scored in a cannabinoid
composite withdrawal index (Hutcheson et al., 1998; Ledent et al., 1999; Tzavara et al., 2000;
Lichtman et al., 2001b). It should be noted that rimonabant can also produce pharmacological
effects in naïve animals that resemble withdrawal symptoms [for a review see(Lichtman and
Martin, 2005)], including increases in ear scratching, head-shakes, and increased grooming
behavior (Cook et al., 1998; Darmani and Pandya, 2000).

Thus, it is critical to include

appropriate vehicle-treated control groups in studies employing a CB1 receptor antagonist to
precipitate cannabinoid withdrawal to control for intrinsic effects of the drug at testing.
Nonetheless, the observation that rimonabant elicits a far greater magnitude of withdrawal-like
behavior (e.g., head shakes and paw tremors) in subjects receiving repeated administration of
THC or repeated exposure to marijuana smoke than control animals (Cook et al., 1998; Wilson
et al., 2006) supports the utility of this precipitated withdrawal model.
Aversive and Subjective Signs: There are few reports examining aversive or emotional
responses in rodents undergoing cannabinoid withdrawal. Rimonabant challenge to THCdependent mice elicited decreased time in open arm time in the elevated plus maze test (Huang
et al., 2010), suggesting the occurrence of an anxiogenic-like state in subjects undergoing
cannabinoid withdrawal, but failed to elicit aversive/dysphoric effects in the conditioned place
aversion test (Hutcheson et al., 1998). In THC-dependent dogs, rimonabant precipitates a
withdrawal syndrome that includes distinct gastrointestinal signs such as diarrhea, vomiting,
excessive salivation as well as decreases in social behavior and increases in restless behavior
and trembling (Lichtman et al., 1998a). Other studies are focusing on subjective signs of
cannabinoid withdrawal. Monkeys chronically treated with THC demonstrated robust
discrimination of the CB1 antagonist rimonabant (McMahon and France, 2003; McMahon,
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2006; Stewart and McMahon, 2010). THC discontinuation produced a similar discriminative
stimulus to rimonabant in THC-treated animals. The data suggest that the interoceptive cues of
THC cessation-induced abstinence are mediated by the CB1 receptor.
Precipitated Withdrawal with Other Cannabinoid Agonists: Rimonabant also precipitates
withdrawal signs following chronic administration of other cannabinoid agonists such as
anandamide, methanandamide, WIN-55,212, CP-55,940 and HU-210 (Rodriguez de Fonseca et
al., 1997; Aceto et al., 1998; Rubino et al., 1998; Aceto et al., 2001). The withdrawal syndrome
precipitated following repeated anandamide administration is not as robust as with other
cannabinoids (Costa et al., 2000; Falenski et al., 2010).
Table 2. Preclinical studies investigating cannabinoid withdrawal employing precipitated and
spontaneous withdrawal procedures

Species

Mouse

Type of

Agonist, Dosing Regimen,

Dependent

Withdrawal

Route of Administration

Variable

Precipitated

THC, 6.5 days: 10 mg/kg

Somatic signs

s.c. (b.i.d.)
Mouse

Precipitated

Reference

(Cook et al.,
1998)

THC, 5.5 days: 10 20

Somatic signs,

(Hutcheson et

mg/kg i.p. (b.i.d.)

adenylyl cyclase

al., 1998)

overshoot in
cerebellum
Mouse

Precipitated

THC, 5.5 days: 20 mg/kg

Somatic signs

i.p. (b.i.d.)
Mouse

Precipitated

(Valverde et al.,
2000)

THC, 6.5 days: 10 mg/kg
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Somatic signs

(Lichtman et al.,

s.c. (b.i.d.)
Mouse

Mouse

Precipitated

2001a)

THC, 5.5 days: 20 mg/kg

Somatic signs, body

(Anggadiredja et

i.p. (b.i.d.)

wt.

al., 2003)

Increased locomotor

(Oliva et al.,

activity, endocrine

2003)

Spontaneous CP, 6.5 days: 0.5 mg/kg i.p.
(b.i.d.)

gene transcription
levels
Mouse

Precipitated

THC, MAR, 5 days: 200

Somatic signs

(Wilson et al.,
2006)

mg; 5 or 10 mg/kg/ i.v.
(s.i.d.)
Mouse

Precipitated

THC, 5.5 days: 20 mg/kg

Somatic signs

i.p. (b.i.d.)
Mouse

Mouse

Precipitated

Precipitated

(Tourino et al.,
2007)

THC, 4.5 days: 25 mg/kg

Somatic signs,

(Huang et al.,

s.c. (b.i.d.)

activity

2009)

THC, 5.5 days: 50 mg/kg

Somatic signs

(Schlosburg et
al., 2009)

s.c. (b.i.d.); 10 mg/kg
(s.i.d.)
Mouse

Precipitated

THC, AEA, 5.5 days: 50

Somatic signs

mg/kg s.c. (b.i.d.)
Mouse

Mouse

Precipitated

Precipitated

(Falenski et al.,
2010)

THC, 10 days: 10 mg/kg

Anxiogenic-like

(Huang et al.,

s.c. (s.i.d.)

effects (plus maze)

2010)

JZL184 (40 mg/kg), THC

Somatic signs

(Schlosburg et

(10,50 mg/kg) 6 days
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al., 2010)

Rat

Precipitated

THC, 4 days: 0.5-4; 2.5-20;

Somatic signs

12.5-100 mg/kg/hr. i.p.
Rat

Precipitated

THC, 6.5 days: 15 mg/kg

1995)
Activity

i.p. (b.i.d.)
Rat

(Aceto et al.,

(Tsou et al.,
1995)

Precipitated,

`THC, 4 days: 12.5-100;

Somatic signs with

(Aceto et al.,

spontaneous

2.5-20; 0.5-4 mg/kg/ 24hr.

precipitated only

1996)

Somatic signs

(Diana et al.,

i.p. (cont.)
Rat

Precipitated

THC, 6.5 days: 15 mg/kg
i.p. (b.i.d.)

Rat

Rat

Precipitated

Precipitated

1998)

CP, 6.5 days: 0.4 mg/kg i.p.

Somatic signs,

(Rubino et al.,

(b.i.d.)

activity

1998)

THC, 6 days: 10-30; 10-40;

Operant rate

(Beardsley and

10-50 mg/kg s.c. (b.i.d.)
Rat

Rat

Martin, 2000)

Precipitated,

WIN, 4 days: 1-8; 2-16; 4-

Somatic signs, body

(Aceto et al.,

spontaneous

16 mg/kg/24 hr. i.p. (cont.)

weight loss

2001)

Precipitated

THC, 4 days: 12.5-100

Somatic signs

(Breivogel et al.,

mg/kg/24 hr. i.p. (cont.)
Rat

Precipitated

2003)
Somatic signs

(Cui et al., 2001)

THC, 8 days: 10 mg/kg i.p.

Somatic signs,

(Gonzalez et al.,

(b.i.d.)

activity

2004)

THC, 10 days: 0.6-1 mg/kg

Somatic signs

(Lichtman et al.,

HU210, 5.5 days: 100
µg/kg i.p. (b.i.d.)

Rat

Dog

Precipitated

Precipitated
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i.v. (b.i.d.)

1998a)

Monkey Spontaneous THC, 10 days 0.05

Operant rate

(Beardsley et al.,

mg/kg/hour i.v.

suppression

1986)

Monkey Precipitated,

THC, Continuous (drug

Somatic signs,

(Stewart and

spontaneous

discrimination study): 1

operant rate

McMahon,

mg/kg (b.i.d.)

suppression

2010)

AEA, anandamide; b.i.d., twice a day; HU-210, a synthetic cannabinoid; i.p., intraperitoneally;
i.v., intravenously; CP, CP 55940; MAR, marijuana; s.c., subcutaneously; s.i.d, once a day;
cont., continuous infusion;THC, Δ9-tetrahydrocannabinol; WIN, WIN 55212-2; (Ramesh et al.,
2011b).
If targeting endocannabinoid catabolic enzymes is indeed a viable approach to treat other
abuse disorders, it is important to know whether these inhibitors would themselves have abuse
or dependence liability. FAAH inhibitors have been extensively investigated in a variety of such
paradigms. Importantly, mice with persistently elevated anandamide levels following inhibition
of FAAH, with the inhibitor URB597 and mice lacking the FAAH enzyme, do not show any
withdrawal symptoms following treatment with rimonabant (Schlosburg et al., 2009; Falenski et
al., 2010). Additionally, it has been demonstrated that URB597 does not produce rewarding
effects in the rat conditioned place preference paradigm, does not substitute for THC in the drug
discrimination paradigm, and is not self-administered in nonhuman primates (Gobbi et al.,
2005; Justinova et al., 2008). There is also supporting biochemical evidence that chronic
treatment with FAAH inhibitors does not lead to long-term neural adaptations. Once-daily
dosing with URB597 for 5 weeks exerted anxiolytic effects without altering CB1 messenger
RNA levels (Bortolato et al., 2007). Likewise, repeated dosing of PF-3845 did not lead to
desensitization or downregulation of CB1 receptors and did not alter CB1 receptor-mediated
synaptic plasticity of hippocampal neurons. In contrast, sustained inactivation of MAGL, by
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repeated treatment with high doses of JZL184 results in loss of its analgesic efficacy and
produces cross-tolerance to the effects of other CB1 agonists in mice. Prolonged MAGL
blockade with JZL184 also results in desensitization and downregulation of CB 1 receptors as
well as impaired endocannabinoid dependent synaptic plasticity (Schlosburg et al., 2010). To
support the preceding literature, we investigated the ability of prolonged MAGL and FAAH
inhibition, using both pharmacologic and genetic approaches, to elicit rimonabant-precipitated
cannabinoid withdrawal in C57 mice.
Methods
Subjects
Male C57BL/6J mice (Jackson laboratories) as well as male FAAH (-/-) and (+/+) mice
backcrossed onto a C57BL/6J background for at least 13 generations (Cravatt et al., 2001)
served as subjects. The mice weighed between 26 and 30 g and were housed 6-8 per cage in a
temperature controlled (20-22oC) environment, in an American Association for the
Accreditation of Laboratory Animal Care-approved facility. The mice were kept on a 12 h light/
dark cycle, with all experiments being performed during the light cycle. Food and water were
available ad libitum. The study was performed with the approval of the Institutional Animal
Care and Use Committee at Virginia Commonwealth University in accordance with the Guide
for the Care and Use of Laboratory Animals.
Drugs
THC and CB1 receptor antagonist rimonabant were obtained from the National Institute
on Drug Abuse (Bethesda, MD). URB597 was purchased from Cayman chemicals (Ann Arbor,
MI). JZL184 and PF-3845 were synthesized as described previously (Ahn et al., 2009; Long et
al., 2009a). THC, PF-3845, JZL184, rimonabant, and URB597 were dissolved in ethanol,
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followed by addition of Emulphor-620 (Rhone-Poulenc, Princeton, NJ), and diluted with 0.9%
saline to form a vehicle mixture of ethanol:emulphor:saline in a ratio of 1:1:18. All injections
were administered in volume of 0.01 ml per 1 g body weight. THC was administered via
subcutaneous (s.c.) injection, whereas PF-3845, JZL184, rimonabant, and URB597 were given
via intraperitoneal (i.p.) injection. PF-3845 and JZL184 were given 2 h before testing, to
coincide with peak levels of AEA and 2-AG elevations, respectively, following systemic
administration (Ahn et al., 2009; Long et al., 2009a). THC was given 30 min before rimonabant
treatment.
Rimonabant-precipitated cannabinoid withdrawal
The mice were given a once daily injection of PF-3845 (10mg/kg, i.p.), JZL184
(4/8/16/40mg/kg, i.p.) or Δ9–THC (10mg/kg s.c.) for 6 days. Under all conditions mice were
give an i.p. injection of rimonabant 2 hr after the last injection of PF-3845, JZL184 and JZL195
or 30 mins after last THC injection.
Behavior was then observed and recorded for 1 hr, using the ANY-maze™ software
after the rimonabant injection. The videos were then scored by time-sampling examining
periods of 5 min intervals, and then moving 5 min ahead on the video starting at minute 5 postrimonabant injection (i.e. 5-10 min, 15-20 min, etc). At the end of the hour video, each animal
had a similar sampled 30 min period observed and scored from their recordings. While several
behavioral endpoints were observed that have been previously described in the literature as
common in mice going through cannabinoid withdrawal (i.e. ptosis, retropulsion, piloerection,
etc.), behaviors scored and presented are the most common, quantifiable, and with the highest
inter-rater reliability (Cook et al., 1998). The primary behavior observed was front paw flutters
that included a range of behavior from single-paw tremors to full fluttering/shaking of both
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paws simultaneously. These motions of the paws are not typical of normal behavior. Also
recorded were head twitches, which generally manifest as rotational shakes of the head, similar
to what is described as “wet dog shakes” in rat.
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Results
2.1. Rimonabant-precipitated withdrawal potential following repeated FAAH inhibition
The aim of this experiment was to examine whether repeated administration of FAAH inhibitors
produces cannabinoid physical dependence. Mice were treated with URB597 (10 mg/kg) or
vehicle twice daily for 5.5 days and were challenged with rimonabant 1 h after their final
injection. Rimonabant produced no significant differences between mice that were given
repeated injections of URB597 and vehicle on paw tremors [p = 0.44; Figure 3A] as well as
head twitching [p = 0.68; Fig. 3B]. We also tested the longer-acting, more selective second
generation FAAH inhibitor, PF-3845. Once-daily treatment with PF3845 (10 mg/kg) elicited
minimal signs following rimonabant precipitation, with no significant differences in the
intensity of paw flutters [p = 0.30; Fig. 3C] and head twitches [p = 0.39; Fig. 3D] in comparison
to vehicle treated mice.
2.2. Rimonabant precipitates withdrawal in mice treated repeated with high dose, but not low
dose, JZL184
In order to examine withdrawal potential from sustained blockade of MAGL, we evaluated
rimonabant-precipitated withdrawal signs in mice treated with either vehicle or JZL184 (4, 8, 16
or 40 mg/kg, i.p./once a day/ 6 days). JZL184 treatment led to an overall significant increase in
the intensity of paw flutters [F(4,42) = 7.551; p<0.001; Fig. 4A]. Post-hoc analysis with
Dunnett’s test showed that repeated treatment with high doses of JZL184 (viz. 16 and 40
mg/kg) resulted in significant increases in incidence of paw flutters, and that withdrawal is not
observed following repeated treatment with low doses of JZL184 (4 and 8 mg/kg). In addition,
JZL184 treatment had no effect on the intensity of head twitches at any of the doses tested (Fig.
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4B). This pattern of findings suggests that sustained and complete blockade of MAGL is
necessary to elicit cannabinoid physical withdrawal.
2.3. Rimonabant precipitates withdrawal in mice with simultaneous complete MAGL and
FAAH inhibition
In order to examine additional withdrawal potential due to simultaneous elevations in
AEA and 2-AG, we treated both FAAH (+/+) and (-/-) mice treated repeatedly with the MAGL
inhibitor JZL184. Upon precipitation with the CB1 antagonist rimonabant, fluttering and head
twitching incidences were recorded as representative of cannabinoid withdrawal. As shown in
Figure 5A, paw tremors were increased in mice treated with repeated JZL184 (40 mg/kg).
Accordingly, there was a significant treatment effect [F(1,69)=45.0, p<0.001] for JZL184,
however there was no effect of genotype on the expression of paw flutters (p=0.29) nor an
interaction between treatment and genotype (p=0.36). When comparing to low-dose (10mg/kg
daily) THC treated mice, JZL184 treated mice showed comparable elevations in fluttering
versus vehicle treated mice (THC vs. JZL184 in FAAH (+/+): p=0.99; Scheffe’s post-hoc; Fig
5A). When examining head twitching response, shown in Figure 5B, there was an effect of
treatment [F(4,77)=3.6, p<0.01]. Post-hoc analysis showed that the THC-treated mice were the
only group to show elevated head twitching above that of vehicle treated groups (p<0.05;
Scheffe’s post-hoc).
To control for the possibility of developmental adaptations in FAAH (-/-) mice, followup experiments were performed using pharmacological means of dual MAGL-FAAH inhibition.
This experiment tested combined administration of JZL184 (40 mg/kg) and PF3845 (10 mg/kg).
Repeated treatment with PF-3845 did not lead to physical withdrawal signs following
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rimonabant challenge. In addition, PF-3845 did not alter the magnitude of paw flutters
following rimonabant challenge in mice given repeated JZL184 [F(3, 28) = 10.0, p < 0.001;
Figure 6A]. While there was an overall treatment effect on head twitches [F(3, 28) = 3.5, p <
0.05; Figure 6B], no individual group was significantly elevated from vehicle.
2.4. Sustained simultaneous partial MAGL and complete FAAH inhibition does not lead to
physical withdrawal on rimonabant challenge
Finally, we evaluated whether repeated treatment with a combination of low-dose JZL184 and
high-dose PF-3845 would also lead to cannabinoid physical withdrawal. This combination was
selected to retain beneficial therapeutic effects of MAGL and FAAH inhibition while avoiding
side-effects of complete MAGL inhibition. In this experiment, mice were repeatedly treated
with either vehicle, JZL184 (40mg/kg) or JZL184 (4 mg/kg) + PF-3845 (10 mg/kg) for 6 days
and followed by rimonabant challenge 2hr after the last injection. While rimonabant precipitated
paw flutters in mice treated with the high dose JZL184, mice treated with the combination of
low dose JZL184 and high dose PF-3845 did not exhibit elevated paw flutters [F(2,21) =
14.101; p<0.001; Fig. 7A]. Neither treatment elicited significantly elevated head twitches in
comparison to vehicle treated mice (Fig. 7B).
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Figure 3. Evaluation of rimonabant-precipitated withdrawal signs following repeated highdosing of FAAH inhibitors.
The first generation, short-acting inhibitor URB597 was given at 10 mg/kg twice daily, while
the more potent and longer-acting inhibitor PF3845 was given daily at a dose of 10 mg/kg.
Neither FAAH inhibitor given repeatedly elicited (A) and (C) paw flutters or (B) and (D) head
twitches compared to vehicle. Data represented as mean ± SEM; n = 8 mice/ group.
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Figure 4. Rimonabant-precipitated withdrawal in mice treated once a day for 6 days with the
MAGL inhibitor JZL184 (4,8,16 or 40 mg/kg) or vehicle.
(A) Rimonabant precipitated a significantly increased intensity of paw flutters in mice treated
with 16 mg/kg and 40 mg/kg JZL184 in comparison to vehicle treated mice. In contrast, mice
treated with 4 mg/kg and 8 mg/kg JZL184 did not exhibit elevated incidences of paw flutters.
(B) Neither dose of JZL184 precipitated a siginificantly altered intensity of head twitches. Data
represented mean ± SEM; n=7-11 mice/ group; *p< 0.05 v/s vehicle control.
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Figure 5. Prolonged elevation of 2-AG, by repeated JZL184 administration, leads to signs of
cannabinoid physical dependence in both FAAH (+/+) and (-/-) mice
(A) Mice treated with 6-day JZL184 (40 mg/kg) show significant paw fluttering withdrawal
behavior upon precipitation with the cannabinoid antagonist rimonabant (10 mg/kg) equally in
both FAAH (+/+) and (-/-) mice. The level of fluttering is comparable to that of a 6-day
moderate dose of THC (10 mg/kg). (B) JZL184 did not elicit head twitch behavior in a manner
similar to THC treatment. Data represented as mean ± SEM; n = 8-15 per group, ***p < 0.001
v/s respective vehicle controls.
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Figure 6. Cannabinoid precipitated withdrawal elicited by prolonged MAGL inhibition is not
altered by simultaneous inhibition of FAAH.
(A) Mice treated with 6-day JZL184 (40 mg/kg) show significant paw fluttering withdrawal
behavior upon precipitation with the cannabinoid antagonist rimonabant (10 mg/kg), which is
absent following 6-day FAAH inhibition via PF-3845 (10 mg/kg), nor enhanced by coadministration of both enzyme inhibitors simultaneously. (B) None of the combination of
enzyme inhibitors elicited altered head twitching behavior. n = 8 per group, ***p < 0.001 v/s
respective vehicle controls.
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Figure 7. Rimonabant does not precipitate withdrawal signs in mice treated repeatedly with a
combination of low dose JZL184 and high dose FAAH inhibitor PF-3845
(A) Rimonabant precipitated significantly elevated paw flutters in mice treated for 6 days with a
high dose of JZL184 (40 mg/kg) but not in those treated with a combination of low-dose
JZL184(4 mg/kg) and PF-3845(10 mg/kg) (B) Head twitching behavior is not altered by either
treatment. Data represented as mean ± SEM; n=8 mice/group; *p<0.05 v/s vehicle control.
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2.5. Discussion
In these experiments we have examined the potential of repeated administration of
MAGL and FAAH inhibitors to produce physical cannabinoid withdrawal in mice. Repeated
treatment with the FAAH inhibitors, URB597 and PF-3845, did not lead to rimonabantprecipitated cannabinoid withdrawal. On the contrary, prolonged treatment with high doses of
the MAGL inhibitor JZL184 by itself or in combination with FAAH inhibition/deletion led to
physical withdrawal on rimonabant challenge. However, repeated treatment with low doses of
JZL184 or a combination of low dose JZL184 with PF-3845 did not lead to cannabinoid
withdrawal.
The ability of prolonged complete MAGL inhibition to elicit precipitated cannabinoid
withdrawal represents a drawback of using these inhibitors in treatment of abuse disorders. It
should be noted that the severity of withdrawal is comparable in magnitude to that of the lowest
level of quantifiable withdrawal from repeated THC treatment. This may indicate that while the
risk of physical dependence may exist, it is minimal compared to exogenous cannabinoid
agonists. Also promising is the observation that though simultaneous complete FAAH and
MAGL inhibition produces enhanced acute cannabinoid-mediated activity (Long et al., 2009c),
there appears to be little enhanced magnitude of precipitated withdrawal compared to MAGL
inhibition alone. This observation was replicated using both genetic and pharmacological tools.
The lack of rimonabant-precipitated cannabinoid withdrawal signs by repeated URB597
or PF3845 treatment adds to a growing body of literature demonstrating that FAAH inhibitors
lack dependence potential (Solinas et al., 2007; Justinova et al., 2008) that are typical of
exogenous cannabinoids. While prolonged treatment with high doses of JZL184 leads to
cannabinoid dependence; repeated treatment with low, pharmacologically active doses of
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JZL184 at 4 and 8 mg/kg did not lead to physical withdrawal. JZL184 at these doses also does
not undergo tolerance to its analgesic effects in the CCI and carrageenan pain assays (Kinsey et
al., Ghosh et al., unpublished data). Finally, rimonabant did not precipitate withdrawal in mice
repeatedly treated with a combination of low-dose JZL184 (4 mg/kg) and PF-3845 (10 mg/kg).
This combination produces augmented anti-allodynic effects in both the CCI and carrageenan
pain assays and repeated treatment does not lead to tolerance or functional CB1 receptor
adaptations in C57BL6/J mice (Wise et al, unpublished data). The lack of dependence and
analgesic tolerance following repeated administration of FAAH inhibitors and low doses of
JZL184 indicates that they are a viable target for the treatment of chronic pain conditions and
abuse disorders.
Thus, elevation of the two primary endocannabinoids in brain leads to different
consequences on physical dependence. These differential actions of prolonged MAGL and
FAAH inhibition are not fully understood and may be partly attributed to (1) higher
concentrations of 2-AG compared with anandamide after sustained blockade of their
degradative enzymes and (2) differences in the efficacy of these endocannabinoids at the CB 1
receptor (Howlett and Mukhopadhyay, 2000) or (3) the result of regionally or neuron selective
production and release of eCBs.

.
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Chapter 3: Effects of inhibition of eCB catabolic enzymes on precipitated somatic opioid
withdrawal signs
A case report from the 19th century suggested that an extract of Cannabis sativa may
ameliorate opiate addiction (Birch, 1889). In this report, a tincture of cannabis extract alleviated
signs of opioid abstinence such as lack of appetite, anorexia, disordered bowels and conscious
delusions in an opium poppy addict. Modern studies corroborated this idea by demonstrating
that THC, the primary psychoactive constituent of cannabis, attenuates the intensity of
naloxone-precipitated opioid withdrawal signs in morphine-dependent rodents (Hine et al.,
1975; Bhargava, 1976). A low oral dose of THC when co-administered with high-dose oral
morphine attenuated the development of dependence and expression of withdrawal signs in
mice (Cichewicz and Welch, 2003). A 30-day pretreatment with THC also resulted in decreased
withdrawal signs in morphine-dependent mice (Jardinaud et al., 2006). The CB1 receptor
appears to play a significant role in modulating dependence to morphine and other opiates. CB 1
(-/-) mice show significantly reduced self-administration of morphine and attenuated naloxoneprecipitated morphine withdrawal signs (Ledent et al., 1999; Lichtman et al., 2001b). Other
exogenous cannabinoid agonists such as AEA and 2-AG have been demonstrated to reduce
signs of naloxone-precipitated withdrawal signs in rodents (Vela et al., 1995; Yamaguchi et al.,
2001). A growing body of literature demonstrates that elevating endogenous cannabinoids by
inhibiting their hydrolytic enzymes offers potential therapeutic benefits, without the undesirable
cannabimimetic actions of the exogenous cannabinoids (Solinas et al., 2007; Ahn et al., 2008;
Justinova et al., 2008; Ahn et al., 2009). It has been reported that there are significant changes in
brain levels of endocannabinoids following chronic morphine treatment (Gonzalez et al., 2003;
Vigano et al., 2004; Caille et al., 2007). These findings support the notion that
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endocannabinoids and the CB1 receptor play an important role in modulating the expression of
opioid withdrawal. In this section, we describe experiments that evaluated whether elevating
endocannabinoids, through the inhibition of their catabolic enzymes, attenuates naloxoneprecipitated withdrawal symptoms in morphine dependent mice. The precipitated withdrawal
model will enable a relatively high throughput initial screen of the inhibitors to assess their antiwithdrawal effects. We investigated the efficacy of the respective MAGL and FAAH inhibitors,
JZL184 and PF-3845, as well as THC to reduce naloxone-precipitated withdrawal signs.
Additionally, we investigated whether the effects of these drugs in modulating opioid
withdrawal are mediated through the CB1 receptor.
Methods
Subjects
Selection of Strain: Initially C57BL6/J (25g; M/F) mice were used for studying withdrawal.
However, morphine (75 mg) pellet implantation led to fatalities in approximately 40% of the
mice, presumably due to respiratory depression or other consequences of overdose. Moreover,
the surviving mice lost a significant portion of body weight during the 3 day period after pellet
implantation. ICR mice (Harlan), on the other hand, did not exhibit significant fatalities and
survived the 3 day pellet implantation without losing body weight. For the FAAH (-/-) studies,
we found that using male mice weighing over 30 g increased survival rate to about 80% in this
study. Given the increased mortality and morbidity observed following morphine pellet
implantation in C57 mice, we selected ICR mice for the rest of the in vivo studies.
Male ICR mice (Harlan laboratories; Indianapolis) as well as male FAAH (-/-) and (+/+)
mice backcrossed onto a C57BL/6J background for at least 13 generations (Cravatt et al., 2001)
served as subjects. The mice weighed between 26 and 30 g and were housed 6-8 per cage in a
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temperature controlled (20-22oC) environment, in an American Association for the
Accreditation of Laboratory Animal Care-approved facility. The mice were kept on a 12 h light/
dark cycle, with all experiments being performed during the light cycle. Food and water were
available ad libitum. The study was performed with the approval of the Institutional Animal
Care and Use Committee at Virginia Commonwealth University in accordance with the Guide
for the Care and Use of Laboratory Animals.
Drugs
Morphine pellets (75 mg), placebo pellets, morphine sulfate, THC, the CB2 receptor
antagonist SR144528, and the CB1 receptor antagonist rimonabant were obtained from the
National Institute on Drug Abuse (Bethesda, MD). Naloxone hydrochloride was purchased
from Cayman chemicals (Ann Arbor, MI). JZL184 and PF-3845 were synthesized as described
previously (Ahn et al., 2009; Long et al., 2009a). THC, PF-3845, JZL184, rimonabant, and
SR144528 were dissolved in ethanol, followed by addition of Emulphor-620 (Rhone-Poulenc,
Princeton,

NJ),

and

diluted

with

0.9%

saline

to

form

a

vehicle

mixture

of

ethanol:emulphor:saline in a ratio of 1:1:18. Naloxone and morphine were dissolved in 0.9%
saline. All injections were administered in volume of 0.01 ml per 1 g body weight. THC and
naloxone were administered via subcutaneous (s.c.) injection, whereas PF-3845, JZL184,
rimonabant, and SR144528 were given via intraperitoneal (i.p.) injection. PF-3845 and JZL184
were given 2 h before testing, to coincide with peak levels of AEA and 2-AG elevations,
respectively, following systemic administration (Ahn et al., 2009; Long et al., 2009a).
Rimonabant, SR144528, and Δ9-THC were given 30 min before naloxone treatment.
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Morphine pellet implantation surgery
In order to induce opioid dependence, mice were implanted with morphine pellets as
previously described (Way et al., 1969). After induction of anesthesia with 2.5% isoflurane, the
fur was shaved, the skin was disinfected with a sterile betadine swab (Purdue products,
Stamford, CT), and a 1 cm horizontal incision was made in the midscapular region, using sterile
surgical scissors.

A 75 mg morphine sulfate pellet was inserted subcutaneously, and the

incision was closed with a sterile staple. The mice were allowed to recover in heated home
cages for 2 h after surgery and then returned to the vivarium until testing.
Naloxone-precipitated opioid withdrawal
Somatic withdrawal signs were scored, as previously described (Schlosburg et al.,
2009). In brief, mice were placed in white acrylic chambers (20x20 cm), with a clear acrylic
front panel and a mirrored back panel for a 30 min acclimation period. The chambers were
enclosed in sound-attenuating cabinets that contained an indirect filtered LED light source and
fans for air circulation and white noise. The mice were briefly removed from the chambers for
naloxone administration and immediately returned to the chambers for a 30 min observation
period. Behavior was recorded using a series of Fire-iTM digital cameras (Unibrain, San Ramon,
CA), and the videos were saved using the ANY-mazeTM video tracking software (Stoelting Co.,
Wood Dale, IL). Chambers were changed between tests and cleaned at the end of testing with
an ammonia based cleanser and left to dry for two days, to allow for odors to dissipate. The
recorded videos were randomized and scored by a trained observer, who was blinded with
respect to treatment condition. The primary behavioral signs of interest were frequency of
jumps and front paw tremors (including single and double paw flutters and twitches, which are
not commonly displayed by naïve mice). The occurrence of diarrhea during the testing period
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was noted. All behaviors were recorded as new incidences when separated by at least 1 s or
interrupted by any other normal behavior. In addition, mice were weighed before and
immediately after the 30 min test session to assess body weight loss.
Extraction and quantification of brain and ileum endocannabinoid levels with LCMS
Mice were implanted with placebo or morphine (75 mg) pellets, as described above. On
day 3, subjects received an s.c. injection of naloxone hydrochloride (1 mg/kg) or saline. Ten
min after naloxone injection, the mice were decapitated, and brains and segments of the ilea
were harvested. Brains were removed and placed on a glass plate on ice for dissection. A
coronal section was taken using the median eminence on the ventral surface as a landmark.
Specific areas of the brain relevant to opioid withdrawal were harvested, including the locus
coeruleus (LC), periaqueductal gray (PAG), and the amygdala. The anterior cut was made
caudal to the optic chiasm and the posterior cut was made at the caudal extent of the
hypothalamus, corresponding to approximately Bregma -0.6 to Bregma -2.6. The amygdala
was dissected using the optic tract medially and the external capsule dorsally as landmarks. The
sample included the amygdaloid nuclei and adjacent piriform cortex. The brainstem was then
placed with the dorsal surface exposed. The PAG section was taken from the anterior superior
colliculus to the caudal inferior colliculus, corresponding to approximately Bregma -3.3 to
Bregma -5.3. Cortex and hippocampus were discarded and the colliculi were removed. Tissue
ventral and lateral to the PAG was removed. The sample included the PAG throughout its
rostral-caudal extent, as well as adjacent reticulum. The next consecutive section was taken by
making a posterior cut at the anterior 1/4 of the cerebellum, corresponding to approximately
Bregma -5.3 to Bregma -5.85. The LC was dissected by removing the cerebellum and the
ventral pons, then isolating the tissue lateral to the fourth ventricle. The sample included the
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locus coeruleus and adjacent parabrachial and tegmental nuclei. The brain areas and ileum
segments were snap frozen in liquid nitrogen and stored at -80°C until lipid extraction.
On the day of processing, tissues were weighed and homogenized with 1.4 ml
chloroform/methanol (2:1 v/v containing 0.0348 mg PMFS/ml) after the addition of internal
standards to each sample (2 pmol AEA-d8 and 1 nmol 2-AG-d8). Homogenates were then
mixed with 0.3 ml of 0.73% w/v NaCl, vortexed, and then centrifuged for 10 min at 4,000 rpm
(4° C). The aqueous phase plus debris were collected and extracted two more times with 0.8 ml
chloroform. The organic phases from the three extractions were pooled and the organic solvents
were evaporated under nitrogen gas. Dried samples were reconstituted with 0.1 ml chloroform
and mixed with 1 ml ice-cold acetone. The mixtures were then centrifuged for 5 min at 3,000
rpm and 4° C to precipitate the proteins. The upper layer of each sample was collected and
evaporated under nitrogen. Dried samples were reconstituted with 0.1 ml methanol and placed
in autosample vials for analysis.
LC/MS/MS was used to quantify AEA and 2-AG. The mobile phase consisted of (10:90)
water/methanol with 0.1% ammonium acetate and 0.1% formic acid. The column used was a
Discovery HS C18, 4.6×15 cm, 3 μm (Supelco, PA). The mass spectrometer was run in
Electrospray Ionization, in positive mode. Ions were analyzed in multiple-reaction monitoring
mode, and the following transitions were monitored: (348>62) and (348>91) for AEA;
(356>62) for AEAd8; (379>287) and (279>269) for 2-AG; and (387>96) for 2-AG-d8. A
calibration curve was constructed for each assay based on linear regression using the peak area
ratios of the calibrators. The extracted standard curves ranged from 0.03 to 40 pmol for AEA
and from 0.05 to 64 nmol for 2-AG.
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Statistical analysis
All data are reported as mean ± SEM. In the behavioral experiments, non-continuous behaviors,
including jumps and paw tremors, are presented as counted observations. The occurrence of
diarrhea was scored as a binary event for the entire 30 min period. Additionally, the mice were
weighed before and after the testing period to determine total body weight loss (g). AEA, and 2AG levels are reported as pmol or nmol per gram of tissue, where applicable. Data were
analyzed using t-test or two-way between measures analysis of variance (ANOVA), followed
by Dunnett’s or Scheffe’s post hoc test. Differences of p<0.05 were considered significant.
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Results
3.1. Naloxone precipitates a profound withdrawal syndrome in morphine-dependent mice
In order to establish the precipitated withdrawal model in our laboratory setting, mice
were implanted with placebo or 75 mg morphine pellets and 72 h later, were challenged with an
s.c. injection of naloxone. As shown in Fig. 8, naloxone precipitated somatic and autonomic
withdrawal signs, including paw tremors (p<0.01), jumping behavior (p<0.01), diarrhea, and a
significant loss in body weight (p<0.01).
3.2. The MAGL inhibitor JZL184 and THC dose-dependently attenuate naloxoneprecipitated withdrawal signs in morphine-dependent mice through the activation of CB1
receptors
In the first set of experiments, we replicated previous work showing that THC attenuated
naloxone-precipitated withdrawal in morphine-dependent mice (Bhargava, 1976). Seventy-two
hours after morphine pellet implantation, mice were treated with vehicle or THC (1, 3, and 10
mg/kg s.c.) and then administered naloxone 30 min later. THC dose-dependently reduced
naloxone-precipitated jumping [F(4,30) = 4.7; p < 0.01; Fig. 9A] and paw fluttering [F(4,30) =
11.3; p < 0.001; Fig 9B], weight loss [F(4,30) = 17.9; p < 0.001; Fig. 8C], and diarrhea (Fig
9D), with the highest dose (10 mg/kg) completely abolishing diarrhea in all mice.
In order to examine the role of MAGL inhibition in opioid withdrawal, we treated
morphine-pelleted mice with either vehicle or JZL184 (4, 16, and 40 mg/kg, i.p.). JZL184
dose-dependently reduced naloxone-precipitated jumping [F(3,26) = 18.8; p < 0.001; Fig. 9A],
paw fluttering [F(3,26) = 4.9; p < 0.01; Fig.9B], diarrhea (Fig. 9D), and weight loss [F(3, 26) =
6.37; p < 0.01; Fig. 9C]. The highest dose of JZL184 (40 mg/kg) completely prevented the
occurrence of diarrhea (Fig. 9D).
52

We next examined whether CB1 or CB2 receptors contribute to the protective effects of
THC and JZL184 in the naloxone-precipitated withdrawal paradigm. The CB1 receptor
antagonist rimonabant (3 mg/kg, i.p.) blocked the protective effects of THC on naloxoneprecipitated jumps (p < 0.05), paw flutters (p < 0.05), weight loss (p < 0.01), and diarrhea (Fig.
8). Rimonabant pretreatment also reversed JZL184-induced attenuation of withdrawal intensity,
as indicated by significant interactions between JZL184 and rimonabant on jumps [F(1, 23) =
8.6; p < 0.01; Fig. 10A], paw flutters [F(1, 23) = 8.2; p < 0.01; Fig. 10B] and weight loss [F(1,
23) = 10.5; p < 0.01; Fig. 10C]. Similarly, the anti-diarrheal effects of JZL184 were completely
reversed by rimonabant treatment (Fig. 10D). In contrast, treatment with the CB2 receptor
antagonist SR144528 (3 mg/kg, i.p.) did not affect either the intensity of naloxone-precipitated
withdrawal signs or JZL184-induced blockade of these withdrawal signs (Fig. 11).

The

interaction between JZL184 pretreatment and SR144528 failed to achieve statistical
significance for jumps [p = 0.24; Fig. 11A], paw flutters [p = 0.76; Fig. 11B] and weight loss [p
=0.55; Fig. 11C]. In addition, SR144528 did not block the anti-diarrheal effects of JZL184
[Fig. 11D]. Taken together, these data indicate that JZL184 attenuates naloxone-precipitated
withdrawal symptoms through a mechanism that requires the activation of CB1 receptor.
3.3. JZL184 maintains its anti-withdrawal effects after repeated treatment.
In order to determine whether prolonged MAGL inhibition maintains anti-opioid
withdrawal efficacy, we treated the mice for six days with the MAGL inhibitor JZL184 (4 or 40
mg/kg, i.p.) during which time a 75mg morphine pellet was implanted on day 3. Withdrawal
was precipitated with an acute treatment of naloxone (1 mg/kg, s.c.) 72 h after pellet
implantation. JZL184 (40mg/kg) reduced naloxone-precipitated jumping [F(2,20) = 5.422; p <
0.01; Fig. 12A] but did not significantly reduce the number of paw flutters (Fig. 12B) (p=0.58).
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There was however, a significant reduction in the amount of weight loss [F(2,20) = 6.871; p <
0.001; Fig. 12C] and percent of mice with diarrhea (Fig. 12D). In contrast, repeated treatment
with JZL184 (4mg/kg) did not affect any of the measured withdrawal symptoms.
3.4. FAAH blockade attenuates somatic signs of naloxone-precipitated morphine withdrawal
through a mechanism that requires the activation of CB1 receptors
To elucidate the role of FAAH in morphine withdrawal, we first examined the impact of
genetic deletion of FAAH on naloxone-precipitated morphine withdrawal. FAAH (-/-) mice vs.
FAAH (+/+) mice on a C57BL/6 background were implanted with 75 g morphine pellets and
challenged with naloxone 72 h later. FAAH (-/-) mice showed significant decreases in jumps
(p<0.01; Fig. 13A), paw flutter incidents (p<0.05; Fig. 13B), and weight loss (p<0.05; Fig. 13C)
compared with FAAH (+/+) mice. Genetic deletion of FAAH did not affect the occurrence of
naloxone-precipitated diarrhea [Fig. 13D]. These data support the idea that FAAH deletion
attenuates the expression of some of the primary signs of naloxone-precipitated opioid
withdrawal.
We next evaluated the irreversible FAAH inhibitor, PF-3845 (10 mg/kg, i.p.) vs. vehicle
on naloxone-precipitated morphine withdrawal. PF-3845 significantly attenuated the frequency
of jumps and paw flutters (Fig. 14A and B). These effects were reversed by rimonabant as
indicated by significant interactions between PF-3845 vs. vehicle and rimonabant vs. vehicle for
jumps [F(1, 41) = 5.9; p <0.05; Fig. 14A] and paw flutters [F(1, 41) = 3.2; p < 0.01; Fig. 14B].
However, PF-3845 did not affect the weight loss during withdrawal (Fig. 14C), or the
occurrence of diarrhea (Fig. 14D) following naloxone challenge. This experiment shows that
acute FAAH inhibition attenuates a subset of withdrawal signs (i.e., jumps and paw flutters) in a
CB1 dependent manner, but does not reduce weight loss or diarrhea.
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3.5. Measurement of endocannabinoid levels in brain following naloxone-precipitated
withdrawal
To determine if naloxone-precipitated withdrawal in morphine-dependent mice altered
levels of endocannabinoids in brain regions associated with opioid dependence, we measured
the levels of AEA and 2- AG in the LC, PAG, and amygdala. Endocannabinoid levels were
also measured in ileum. None of the treatments altered the levels of either endocannabinoid in
any of the brain regions of interest or in the ileum (Table 1).
Although it is well established that acute administration of JZL184 and PF-3845
respectively increases 2-AG and AEA brain levels (Schlosburg et al., 2010), the effects of these
inhibitors on endocannabinoid levels have not been measured in gastrointestinal tissue. Thus, in
the next experiment, we treated naïve mice with the enzyme inhibitors and quantified
endocannabinoids in ileum. As shown in Table 3, PF-3845 (10 mg/kg) significantly increased
AEA, but not 2-AG, in the ileum.

In contrast, JZL184 did not significantly alter either

endocannabinoid in ileum.
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Figure 8. Naloxone precipitates somatic withdrawal signs in mice implanted with a
subcutaneous morphine pellet (75 mg) for 3 days but not in mice implanted with a placebo
pellet.
The withdrawal signs measured included: (A) jumps, (B) paw flutters, (C) weight loss and (D)
diarrhea. Data expressed as mean ± SEM. *p,0.05; **p < 0.01 v/s placebo control; n = 6-8
mice/group
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Figure 9. The primary psychoactive constituent of cannabis sativa THC and the irreversible
MAGL inhibitor JZL184 attenuate the intensity of naloxone-precipitated withdrawal signs in a
dose-dependent manner.
THC (30 min pretreatment) or JZL184 (2 h pretreatment) was given prior to naloxone (1
mg/kg, s.c.). Rimonabant (3 mg/kg, i.p.) given 30 min before naloxone challenge antagonized
the anti-withdrawal effects of THC (10 mg/kg, i.p.). The withdrawal signs measured included:
(A) jumps, (B) paw flutters, (C) weight loss and (D) diarrhea. Data expressed as mean ± SEM
for panels A-C. ***p<0.001, **p<0.01, *p<0.05 vs. vehicle; # p<0.05 vs. 10mg/kg THC; ##
p<0.01 v/s THC(10mg/kg); n = 6-8 mice/group.
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Figure 10. The MAGL inhibitor JZL184 attenuates the intensity of naloxone-precipitated
morphine withdrawal signs in a CB1 receptor dependent manner
Rimonabant (3 mg/kg, i.p.) administered 90 min after JZL184 (40 mg/kg, i.p.) blocked the antiwithdrawal effects of JZL184. The withdrawal signs measured were: (A) jumps, (B) paw
flutters, (C) weight loss and (D) diarrhea. Data expressed as mean ± SEM for panels A-C.
**p<0.01 vs. vehicle; ## p<0.01 vs. JZL184-vehicle; n = 6-8 mice/group.
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Figure 11. The reduction of intensity of naloxone-precipitated morphine withdrawal signs is not
CB2 receptor mediated.
The CB2 antagonist SR144528 (3 mg/kg, i.p.) did not reverse the anti-withdrawal effects of
JZL184 (40 mg/kg, i.p.). The withdrawal signs measured were: (A) jumps, (B) paw flutters, (C)
weight loss and (D) diarrhea. Data expressed as mean ± SEM for panels A-C. ***p<0.001,
**p<0.01 vs. vehicle; n = 7-8 mice/group.
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Figure 12: JZL184 maintains it anti-withdrawal effects following repeated treatment in
morphine-dependent mice
Repeated treatment with JZL184 (40mg/kg, once a day, 6 d) reduced the intensity of jumps,
weight loss and occurrence of diarrhea, but repeated treatment with a low (4mg/kg) dose did not
have anti-withdrawal effects. The withdrawal signs measured were (A) jumps, (B) paw flutters,
(C) weight loss and (D) diarrhea. Data expressed as mean ± SEM for panels A-C. **p<0.01,
*p<0.05 vs. vehicle; ### p<0.001, # p < 0.05 vs. PF-3845; n=11-12 mice/group.
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Figure 13. FAAH (-/-) mice display attenuated naloxone-precipitated withdrawal signs.
The withdrawal signs measured were (A) jumps, (B) paw flutters, (C) weight loss and (D)
diarrhea. Data expressed as mean ± SEM for panels A-C. **p<0.01, *p<0.05 vs. FAAH (+/+)
group; n=6-7 mice/group.
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Figure 14. The FAAH inhibitor PF-3845 attenuates a subset of naloxone-precipitated morphine
withdrawal signs in a CB1 receptor dependent manner.
PF-3845 (10 mg/kg, i.p.) reduced the intensity of jumps and paw flutters, which was reversed
by rimonabant (3 mg/kg, i.p.). The withdrawal signs measured were (A) jumps, (B) paw flutters,
(C) weight loss and (D) diarrhea. Data expressed as mean ± SEM for panels A-C. **p<0.01,
*p<0.05 vs. vehicle; ### p<0.001, # p < 0.05 vs. PF-3845; n=11-12 mice/group.
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Table 3. Endocannabinoid levels in brain regions associated with opioid withdrawal
AEA (top) and 2-AG (bottom) levels are not altered following treatment with either morphine
or placebo and acute challenge with either saline or naloxone (1 mg/kg, s.c.). Data expressed as
mean ± SEM; p<0.05 v/s Placebo-saline

AEA levels (pmol/g)
Treatment

LC

PAG

Amygdala

Ileum

Placebo-saline

3.7 ± 0.3

4.2 ± 0.3

9.5 ± 0.8

1.2 ± 0.3

Morphine- saline

5.1 ± 1.0

4.5 ± 0.6

8.2 ± 0.6

1.3 ± 0.2

Placebo- naloxone

4.7 ± 0.4

4.8 ± 0.5

9.1 ± 1.1

1.5 ± 0.1

Morphine- naloxone

4.3 ± 0.4

4.6 ± 0.5

8.2 ± 0.6

1.7 ± 0.2

2-AG levels (nmol/g)
LC

PAG

Amygdala

Ileum

Placebo-saline

6.4 ± 0.4

11.1 ± 0.9

11.6 ± 1.3

5.6 ± 0.7

Morphine- saline

7.0 ± 0.5

11.8 ± 1.5

10.8 ± 0.9

5.6 ± 1.1

Placebo- naloxone

6.9 ± 0.7

11.7 ± 2.4

17.7 ± 4.2*

5.8 ± 1.0

Morphine- naloxone

6.3 ± 0.6

10.2 ± 0.8

17.0 ± 3.6*

6.6 ± 1.9
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3.6. Discussion
In these experiments, we report that inhibition of the endocannabinoid catabolic
enzymes, MAGL or FAAH, reduces naloxone-precipitated withdrawal in an in vivo model of
morphine dependence. While previous studies have demonstrated that THC and other
cannabinoid agonists reduce precipitated withdrawal in opiate-dependent rodents (Bhargava,
1976; Vela et al., 1995; Yamaguchi et al., 2001), this is the first report demonstrating that
elevating endocannabinoids by blocking their hydrolysis represents a viable approach to reduce
opioid withdrawal. Acutely administered JZL184, which preferentially inhibits MAGL over
FAAH and selectively raises brain 2-AG, but not anandamide in vivo (Long et al., 2009a; Long
et al., 2009b), completely blocked all measured behavioral effects of precipitated withdrawal,
including paw flutters, jumps, diarrhea, and weight loss. Rimonabant blocked these effects,
indicating a necessary role of CB1 receptors. On the other hand, the CB2 receptor antagonist
SR144528 did not block the effects of JZL184 indicating that CB2 receptors are not required for
its anti-withdrawal effects. Repeated treatment with high doses of JZL184 led to maintenance of
anti-withdrawal effects. While FAAH (-/-) mice showed a reduction in all three measures of
naloxone-precipitated withdrawal, PF-3834 reduced only naloxone-precipitated jumping and
paw flutters, but did not attenuate diarrhea or body weight loss.
In this set of studies, we have examined the effects of FAAH and MAGL inhibitors on
naloxone-precipitated opioid withdrawal signs. The precipitated withdrawal model uses an
antagonist (i.e naloxone) to abruptly halt MOR activation by morphine allowing expression of
symptoms mimicking that of natural withdrawal. This model offers potential advantages that the
syndrome is short in duration and the symptoms observed are reliably and overtly quantifiable.
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The pharmacological effects of JZL184 undergo tolerance in a variety of pain assays
after repeated treatment at high doses (Schlosburg et al., 2010). Here we report that the antiwithdrawal effects of high dose JZL184 do not undergo tolerance. This may be due to different
signaling pathways at the CB1 receptor or distinct neural substrates mediating withdrawal,
different from those involved in mediating analgesia.
In our studies, induction of withdrawal in morphine-dependent mice did not alter AEA
or 2-AG levels in brain areas associated with opiate withdrawal, including LC, PAG, and
amygdala, though 2-AG levels have been reported to be increased in other brain regions of rats
treated repeatedly with morphine (Vigano et al., 2003). Likewise, chronic heroin selfadministration in rats does not produce overt CB1 receptor functional changes in LC, PAG,
amygdala, and other brain structures (Sim-Selley et al., 2000). This pattern of results argues
against direct activation of the endocannabinoid system during opioid withdrawal. On the other
hand, inhibitors of endocannabinoid hydrolysis elevate AEA and 2-AG levels in whole brain
(Ahn et al., 2009; Long et al., 2009a; Long et al., 2009b) as well as in brain regions associated
with opiate withdrawal. Thus, MAGL and FAAH inhibitors attenuate the expression of
withdrawal signs by extending the activity of endocannabinoids at the CB 1 receptor.
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Chapter 4: Effect of inhibition of eCB catabolic enzymes on spontaneous opioid
withdrawal signs
In Chapter 3, we have established that inhibitors of endocannabinoid catabolic enzymes
reduce naloxone-precipitated opioid withdrawal signs. The precipitated withdrawal model is
widely used because it produces a severe withdrawal response with a quick onset in a short
duration of time. The spontaneous withdrawal procedure, on the other hand, more closely
models the antecedents of withdrawal occurring in opioid addicts, though it has a slower
throughput than the precipitated withdrawal model. Thus, potential treatments for opioid
withdrawal are not evaluated for their efficacy in attenuating spontaneous withdrawal signs as
often as in precipitated withdrawal models. In mice, abrupt cessation of morphine
administration leads to expression of withdrawal signs similar to that elicited by an opioid
antagonist. Particularly, platform jumping is commonly observed and considered to be a reliable
indicator of the induction of withdrawal (Way et al., 1969). These somatic signs last for up to 48
h, with peak intensity of withdrawal occurring between 6-8 h following cessation of opioid
administration. This model also allows for examining the anti-withdrawal effects and selecting
agents that have a sustained half-life throughout the time course of withdrawal. Despite the fact
that the spontaneous withdrawal procedure presents with considerable challenges, it is
considered to possess more face validity than precipitated withdrawal procedure for modeling
human opioid withdrawal.
In this chapter, we investigated the dose-response relationship of the MAGL inhibitor
JZL184 to reduce spontaneous withdrawal induced jumps, paw flutters, head shakes, diarrhea
and weight loss in mice implanted with morphine pellets. In addition, we tested the
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effectiveness of a combination of low-dose JZL184 and high dose of the FAAH inhibitor PF3845 in reducing abrupt morphine withdrawal signs. The selective CB1 receptor antagonist,
rimonabant was employed to assess cannabinoid receptor involvement of the anti-withdrawal
effects of JZL184 and the combination. In order to evaluate whether compensatory changes of
endocannabinoid system occurs following treatment with MAGL and FAAH inhibitors in ICR
mice, endocannabinoid and arachidonic acid (AA) levels were quantified in whole brain. In
addition, we measured changes in CB1 receptor number and G-protein activation following
repeated treatment with these inhibitors.
Methods
Subjects
Male ICR mice (Harlan laboratories; Indianapolis) weighing between 26 and 30 g served
as subjects. The mice were housed 4-5 per cage in a temperature controlled (20-22oC)
environment, in an American Association for the Accreditation of Laboratory Animal Careapproved facility. The mice were kept on a 12 h light/ dark cycle, with all experiments being
performed during the light cycle. Food and water were available ad libitum. The study was
performed with the approval of the Institutional Animal Care and Use Committee at Virginia
Commonwealth University in accordance with the Guide for the Care and Use of Laboratory
Animals.
Drugs
Morphine pellets (75 mg), placebo pellets, morphine sulfate, THC, and rimonabant were
obtained from the National Institute on Drug Abuse (Bethesda, MD). Naloxone hydrochloride
was purchased from Cayman chemicals (Ann Arbor, MI).
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JZL184 and PF-3845 were

synthesized as described previously by Organix Inc. (Woburn, MA) (Ahn et al., 2009; Long et
al., 2009a). THC, PF-3845, JZL184 and rimonabant were dissolved in ethanol, followed by
addition of Emulphor-620 (Rhone-Poulenc, Princeton, NJ), and diluted with 0.9% saline to form
a vehicle mixture of ethanol:emulphor:saline in a ratio of 1:1:18. Naloxone and morphine were
dissolved in 0.9% saline. All injections were administered in a volume of 0.01 ml per 1 g body
weight. THC and naloxone were administered via subcutaneous (s.c.) injection, whereas PF3845, JZL184 and rimonabant were given via intraperitoneal (i.p.) injection. For spontaneous
withdrawal studies all treatments were given 1 h before the first test time-point.
Morphine pellet implantation surgery
In order to induce opioid dependence, mice were implanted with morphine pellets as
previously described (Way et al., 1969). After induction of anesthesia with 2.5% isoflurane, the
fur was shaved, the skin was disinfected with a sterile betadine swab (Purdue products,
Stamford, CT), and a 1 cm horizontal incision was made in the midscapular region, using sterile
surgical scissors.

A 75 mg morphine sulfate pellet was inserted subcutaneously, and the

incision was closed with a sterile staple. The mice were allowed to recover in heated home
cages for 1 h after surgery and then returned to the vivarium until testing.
Spontaneous morphine withdrawal
In withdrawal experiments, mice were implanted with 75 mg morphine pellets. Approximately,
71 h after pellet implantation, mice were weighed and assessed for baseline withdrawal
behavior. The pellets were removed under light isoflurane anesthesia approximately 72 h after
implantation. The mice were housed individually in cages that were placed on heating pads for
2 h. At 1 h after pellet removal, groups received an injection of drug or vehicle. The animals
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were observed for spontaneous withdrawal signs for 15 min intervals at 2, 4, 6 and 8 h postpellet removal. The mice continued to be housed singly throughout the testing period, and food
and water were available ad libitum, except during the 15 min observation periods. Spontaneous
withdrawal signs were quantified using a procedure that was adapted from Way et a. (1969).
The percentage of mice that jumped off a circular platform (15 cm diameter x 70 cm height), the
total number of paw tremor and head shake incidences, and body weight were recorded at each
time point. Paw flutters and head shakes were each pooled across all time points to represent the
total number of incidences of the behaviors observed. The percentage of mice presenting with
diarrhea across the 8 h test session was also recorded. Finally, the mice were weighed at the end
of each testing period.
Behavioral assessment of cannabinoid activity
For this study mice were injected with either vehicle (JZL184 40 mg/kg or PF3845 10 mg/kg,
i.p.) on the sixth day (single groups), or drug (JZL184 40 mg/kg, JZL184 4mg/kg, PF3845 10
mg/kg, or JZL184 4 mg/kg + PF-3845 10 mg/kg i.p.). Catalepsy was evaluated using the bar
test, in which the front paws of each subject were placed on a rod (0.75 cm diameter) that was
elevated 4.5 cm above the surface. Mice were timed if they remained motionless with their
paws on the bar (with the exception of respiratory movements), and the time motionless from 3
attempts to place on the bar were totaled with a cutoff of 60 s. Hyper-reflexive popping and
jumping away from the bar was also scored. In the tail immersion test, each mouse was placed
head first into a small bag fabricated from absorbent under pads (VWR Scientific Products; 4
cm diameter, 11 cm length) with the tail out of the bag. The experimenter gently held the mouse
and immersed approximately 1 cm of the tip of the tail into a water bath maintained at 52.0°.
The latency for the animal to withdraw its tail from the water within a 10s cutoff time was
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scored. Rectal temperature was determined by inserting a thermocouple probe 2.0 cm into the
rectum and temperature was obtained from a telethermometer. Before any injections, baseline
tail nociceptive latencies and rectal temperatures were assessed for all tests.
Agonist-stimulated [35S]GTPγS binding
Mice were sacrificed by decapitation, and the whole brain, minus olfactory bulbs, was removed.
Tissues were stored at -80°C until use. Samples were placed in 5 ml of cold membrane buffer
(50 mM Tris-HCl, 3 mM MgCl2, 1 mM EGTA, pH 7.4) and homogenized. Homogenized
samples were centrifuged at 50,000g at 4°C for 10 min. The supernatant was removed and
samples were resuspended in 5 ml of assay buffer A (50 mM Tris-HCl, 3 mM MgCl2, 0.2 mM
EGTA, 100 mM NaCl, pH 7.4). Protein concentration was determined by the Bradford method
(Bradford, 1976). To reduce basal activation by adenosine receptors, preincubation for 15 min
at 30°C with adenosine deaminase (3 mU/ml) in assay buffer was performed before addition to
the final buffer mixture. Concentration-effect curves were generated by incubating 5 μg of
membrane protein in assay buffer B (assay buffer A plus 1.25 g/l BSA), with 3 nM to 3 μM
CP55,940, 30 μM GDP, and 0.1 nM [35S]GTPγS in 0.5-ml total volume. Solutions were
vortexed and to incubated for 2 h at 30°C. Basal binding was measured in the absence of
agonist, and nonspecific binding was measured in the presence of 20 μM unlabeled GTPγS. The
reaction was terminated by vacuum filtration though Whatman GF/B glass fiber filters,
followed by three washes with 4°C Tris buffer (50 mM Tris-HCl, pH 7.4). Bound radioactivity
was determined by liquid scintillation spectrophotometry at 95% efficiency after 10-h extraction
in ScintiSafe Econo 1 scintillation fluid.
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[3H]-SR141716A binding
Membranes were prepared as described above. Membrane proteins (10 μg) were incubated with
0.1-2.5 nM [3H]-SR141716A in 50 mM Tris-HCl, 3 mM MgCl2 , 0.2 mM EGTA, 100 mM
NaCl, 1.25 g/L BSA, pH 7.4 in the presence or absence of 5 μM unlabeled rimonabant (to
determine non-specific binding) for 90 min at 30°C. The reaction was terminated by vacuum
filtration though Whatman GF/B glass fiber filter that was pre-soaked in Tris buffer containing
5 g/L BSA (Tris-BSA), followed by three washes with 4°C Tris-BSA. Bound radioactivity was
determined by liquid scintillation spectrophotometry at 45% efficiency after extraction in
ScinitSafe Econo 1 scintillation fluid.
Statistical analysis
All data are reported as mean ± SEM. In the behavioral experiments, non-continuous
behaviors, including head shakes and paw tremors, are presented as counted observations. The
occurrence of jumps and diarrhea was scored as a binary event for the entire 15 min period for
each time point. Weight loss (g) was calculated by subtracting the body weight at the conclusion
of each 15 min observation period from the pre-pellet removal weight. Data were analyzed
using one-way or two-way between measures analysis of variance (ANOVA), followed by
Dunnett’s or Scheffe’s post hoc test. The percentage of mice between groups presenting with
diarrhea and percentage of mice that jumped off platforms were compared by the z test of two
proportions.
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Results
4.1. Abrupt removal of morphine pellet induces opiate withdrawal signs in mice
As shown in Figure 15, morphine pellet removal increased the percentage of mice
jumping from the platform (4-8 h; p<0.05; Fig 15A), increased the incidences of paw flutters (224 h; p<0.05; Fig 15B) and head shakes (2-24 h; p<0.05; Fig 15C), and resulted in greater
weight loss (4-24 h; p<0.05; Fig 15 D) compared to mice that had placebo pellets removed.
Morphine pellet removal also resulted in diarrhea (Fig 15E).
4.2. JZL184 dose-dependently attenuates spontaneous withdrawal signs in a CB1-dependent
manner
In order to examine whether MAGL inhibition reduces spontaneous withdrawal signs, we
treated morphine-pelleted mice with either vehicle or JZL184 (4, 16, or 40 mg/kg, i.p.). Both 40
and 16 mg/kg JZL184 significantly reduced jumping at 4, 6 and 8 h post-pellet removal (Fig.
16A). JZL184 dose-responsively reduced the intensity of total paw flutters [F(3,28) = 26.4; p <
0.001; Fig. 16B], total head shakes [F(3,28) = 12.1; p < 0.001; Fig. 16C ], and weight loss
across all time points [F(12, 112) = 4.0; p < 0.001; Fig. 16D]. All doses of JZL184 completely
blocked the occurrence of diarrhea in morphine-dependent mice undergoing withdrawal (Fig.
16E).
We next evaluated whether the anti-withdrawal effects of JZL184 were mediated by the
CB1 receptor. An additional group of mice was co-administered JZL184 (40 mg/kg) and
rimonabant (3mg/kg, i.p). Rimonabant reversed the anti-withdrawal effects of JZL184, as
indicated by the increased percentage of spontaneous withdrawal jumps (Fig. 16A), number of
total paw flutters [F(2,22) = 24.8; p < 0.001; Fig. 16B], number of total head shakes [F(2,22) =
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9.7; p < 0.001; Fig. 16C] and intensity of weight loss [F(8,84) = 5.3; p < 0.001; Fig. 16D]. In
addition, rimonabant also reversed the anti-diarrheal effects of JZL184 (Fig 16E).
4.3. The FAAH Inhibitor PF-3845 and THC also reduce the intensity of abrupt withdrawal
signs
To elucidate the role of FAAH in morphine withdrawal, we evaluated the irreversible FAAH
inhibitor, PF-3845 (10 mg/kg, i.p.) on spontaneous morphine withdrawal. PF-3845 significantly
attenuated the frequency of paw flutters [p < 0.001; Fig 17B] and head shakes [p < 0.001; Fig
17D], but did not affect jumping behavior, weight loss or the expression of diarrhea (Fig 17A,
17D and 17E). The phytocannabinoid THC blocked withdrawal induced jumping (Fig 17A),
reduced the intensity of total paw flutters [p < 0.001; Fig 17B], head shakes [p < 0.01; Fig 17C]
and weight loss [F(4,52) = 3.966; p < 0.01; Fig. 17D], and completely prevented the occurrence
of diarrhea (Fig. 18E). This experiment shows that acute FAAH inhibition attenuates a subset of
withdrawal signs (i.e., paw flutters and head shakes), while the cannabinoid receptor agonist
THC attenuates all the measured behavioral signs.
4.4. Combined partial MAGL inhibition and complete FAAH inhibition attenuates
spontaneous withdrawal signs through the activation of CB1 receptors
To evaluate the role of dual inhibition of MAGL and FAAH on spontaneous opioid withdrawal
signs a set of mice was co-administered a low dose of JZL184 (4 mg/kg, i.p.) or vehicle and a
high dose of PF-3845 (10 mg/kg, i.p.) or vehicle. These doses were selected to optimize the
anti-opioid withdrawal effects of endocannabinoid catabolic inhibitors and avoid the
dependence potential of high doses of JZL184. Combination of JZL184 and PF-3845, but not
either drug alone, significantly reduced jumping at 4, 6, and 8 h after morphine pellet removal
(Fig. 18A). In addition, the combination as well as each drug by itself significantly reduced the
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intensity of total paw flutters [F(3,26) = 12.3; p < 0.001; Fig. 18B] and head shakes [F(3,26) =
4.4; p < 0.01; Fig. 18C ]. However, only the combination reduced the intensity of weight loss
[F(12,104) = 1.7; p < 0.01; Fig. 18D], as indicated by significant interactions between group and
time. In addition, the combination treatment significantly blocked the occurrence of diarrhea
while the groups treated with either drug alone presented with diarrhea (Fig. 18E). Either
individual treatment reduced only the intensity of paw flutters and head shakes, whereas the
combination reduced the full spectrum of abrupt withdrawal signs.
Rimonabant completely blocked the anti-withdrawal effects of combined administration
of JZL184 and PF-3845, indicating a CB1 receptor mechanism of action. Rimonabant cotreatment completely reversed the effects of the combination as indicated by a significant
interaction for paw flutters [F(1,37); p<0.01, Fig 19B], head shakes [F(1,37); p<0.05; Fig 19C]
and weight loss [F(12,108)=2.752; p<0.01; Fig 19D]. In addition, rimonabant also reversed the
effects of the combination in blocking jumps and the occurrence of diarrhea (Fig 19A & E).
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Figure 15. Evaluation of spontaneous withdrawal signs in mice.
Removal of morphine pellets leads to increased spontaneous withdrawal signs compared to
mice implanted with placebo pellets. (A) Percentage of mice that displayed platform jumping,
(B) number of paw flutters, (C) number of head shakes, (D) weight loss and (E) expression of
diarrhea. Data expressed as mean ± SEM for panels B-D. *p<0.05,**p<0.01,***p<0.001 vs.
placebo; n = 6-9 mice/group.
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Figure 16. JZL184 reduces spontaneous withdrawal signs in a CB1-dependent manner
The MAGL inhibitor JZL184 dose-dependently attenuates the intensity of the following
spontaneous withdrawal signs in morphine-dependent mice through the activation of CB1
receptors. Rimonabant (3 mg/kg) when co-administered with JZL184 (40mg/kg) blocked it antiwithdrawal effects. The withdrawal signs measured include (A) jumps, (B) paw flutters, (C)
head shakes, (E) weight loss and (E) diarrhea. Data expressed as mean ± SEM for panels B-D.
*p<0.05 vs. morphine control; # p<0.05 v/s JZL184 treated group; n = 7-9mice/group.
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Figure 17. THC and PF-3845 reduce spontaneous withdrawal signs
The phytocannabinoid THC attenuates the intensity of the spontaneous withdrawal signs in
morphine-dependent mice while the FAAH inhibitor PF-3845 reduces the intensity of some
withdrawal signs. The withdrawal signs measured include (A) jumps, (B) paw flutters, (C) head
shakes, (E) weight loss and (E) diarrhea. Data expressed as mean ± SEM for panels B-D.
*p<0.05 vs. morphine control; n = 7-8 mice/group.
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Figure 18. Combination of low-dose JZL184 and high-dose PF-3845 reduces abrupt withdrawal
signs
The combination of low dose of the MAGL inhibitor JZL184 (4 mg/kg) and high dose of the
FAAH inhibitor PF-3845 (10 mg/kg) reduces the intensity of the spontaneous withdrawal signs
in morphine dependent mice to a greater extent than either inhibitor by itself. The withdrawal
signs measured include (A) jumps, (B) paw flutters, (C) head shakes, (E) weight loss and (E)
diarrhea. Data expressed as mean ± SEM for panels B-D. *p<0.05 vs. morphine control; n = 78mice/group.
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Figure 19: Effects of the combination of partial MAGL and complete FAAH inhibition are CB1
mediated
Rimonabant blocks the effects of the combination of low dose of the MAGL inhibitor JZL184
(4 mg/kg) and high dose of the FAAH inhibitor PF-3845 (10 mg/kg) in reducing the intensity of
the spontaneous withdrawal signs in morphine dependent mice. The withdrawal signs measured
include (A) jumps, (B) paw flutters, (C) head shakes, (E) weight loss and (E) diarrhea. Data
expressed as mean ± SEM for panels B-D. *p<0.05 vs. morphine control; n = 10-11 mice/group.
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4.5. Evaluation of tetrad effects and measurement of endocannabinoid levels in brain
following acute MAGL and FAAH inhibition
Mice treated acutely with either vehicle, THC (10 mg/kg), low-dose JZL184 (4 mg/kg),
PF-3845 (10 mg/kg), combination of low-dose JZL184 + PF-3845 and high-dose JZL184 (40
mg/kg) were assessed in the tetrad assay (Table 4). After assessment of tetrad effects, brains
were harvested at 2h post-injection. Neither treatment produced any change in the open field
locomotor behavior or cataleptic effects in ICR mice. Additionally, only THC produced
significant hypothermia (Δ oC= -2.02 ± 0.7; p<0.05) and antinociception (Δ sec= 2.21 ± 0.9;
p<0.05) in the tail withdrawal test, while the other treatments had no effect.
The elevation of whole-brain endocannabinoid levels following acute and prolonged
MAGL and FAAH inhibition by JZL184 and PF-3845 has been previously established in
C57BL/6J mice (Long et al., 2009a; Schlosburg et al., 2010). Additionally, MAGL inhibition
reduces AA levels in the brain which is a hydrolytic product of 2-AG catabolism. A recent
report suggests that 2-AG hydrolysis by MAGL is responsible for up to 80% of AA generated in
the brain (Ahn et al., 2009; Long et al., 2009a; Nomura et al., 2011). To determine whether
acute treatment with MAGL and FAAH inhibitors produces altered levels of endocannabinoids
and arachidonic acid in whole brains from ICR mice we measured the levels of AEA, 2AG,OEA, PEA and AA. Acute treatment with low-dose JZL184 (4 mg/kg), alone and in
combination with FAAH inhibition, significantly elevated 2-AG levels 2-4 fold [F(3,28) = 25.7;
p<0.001; Fig.20A]. Notably, mice treated with the combination showed a higher elevation in 2AG than mice treated with JZL184 (4mg/kg) alone. High-dose JZL184 elevated 2-AG levels
approximately 10 fold (p<0.001 v/s vehicle control. Fig. 19A), comparable to levels observed in
C57BL/6J mice (Long et al., 2009b). Acute treatment with high-dose JZL184 led to
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approximately 40% decrease in AA levels (p<0.05) and the combination moderately lowered
AA levels [F(3,28) = 4.6; p<0.01, Fig. 20B] compared to vehicle controls. When examining
endocannabinoid accumulation in brain 2 h following acute treatment with PF-3845 or
combination of PF-3845+JZL184, AEA was elevated more than 8-fold above that of vehicle
[F(3,28)=309.3; p<0.001; Fig 20C)].
4.6. Brain CB1 receptors are impaired by prolonged MAGL, but not FAAH blockade
Genetic or prolonged pharmacological disruption of MAGL, but not FAAH, leads to
down-regulation and desensitization of CB1 receptors in C57BL/6J mice (Falenski et al., 2010;
Schlosburg et al., 2010). To determine whether these CB1 adaptations also occurred in outbred
ICR mice, we measured endocannabinoid and AA levels, examined CB1 receptor expression
and function through specific binding of [ 3H]-SR141716A and CP55,940-stimulated [35S]GTPγS binding, respectively, in whole-brain homogenates from mice treated with either
vehicle, low-dose JZL184 (4 mg/kg), PF-3845 (10 mg/kg), combination of JZL184 (4mg/kg) +
PF-3845 (10mg/kg), or high-dose JZL184 (40 mg/kg). Mice were treated with inhibitors/vehicle
once a day for 5 days and brains were harvested 24 h later or once a day for 6 days and brains
extracted 2 h later.
Repeated low dose JZL184 did not lead to increased levels of 2-AG at 24 h, though high
dose JZL184 increased brain 2-AG levels at this time point approximately 8 fold compared to
vehicle (p<0.001; Fig. 21A). Repeated treatment with high-dose JZL184 led to about 40%
decrease in AA levels (p<0.05) and the combination moderately lowered AA levels [repeated
treatment, F(3,20)= 3.7; p<0.05, Fig. 21B] compared to vehicle controls. On the contrary, low
dose JZL184 elevated 2-AG levels, at 2 h following repeated dosing, approximately 10 fold
while the combination elevated 2-AG 8-fold [F(4,24)=62.445; p<0.001; Fig. 20D]. These
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treatments also significantly attenuated AA levels by approximately 40%. The high dose of
JZL184 elevated 2-AG levels almost 20-fold and produced about 70% decrease in AA levels
[F(4,24) = 19.5; p<0.05, Fig. 21E] compared to vehicle controls. Neither low dose nor high dose
of repeated JZL184 injections produced significant increases in whole brain AEA levels at 2 h
or 24 h (Fig. 21 C & F). Prolonged FAAH blockade did not induce changes in AEA or 2-AG
levels 24 h post treatment. Prolonged FAAH inhibition with or without concomitant MAGL
inhibition led to elevated AEA levels at 2 h similar to acute treatment [F(4,24)=46; p<0.001; Fig
21F].
Consequently, the CP55,940-stimulated [35S]-GTPγS concentration-effect curves (Fig.
22 A and B) display a substantial reduction in E max of 44% from mice receiving repeated high
dose-JZL184 (40 mg/kg). Two-way ANOVA analysis shows that there is a significant
attenuation of Emax by JZL184 (4 mg/kg) treatment irrespective of simultaneous FAAH
inhibition [F(1,20)=11.9; p<0.01; Fig.22A]. Nonlinear sigmoidal regression on the activation
curves revealed a significantly lower maximal efficacy of agonist stimulation (E max). Repeated
treatment with high dose-JZL184 (40 mg/kg) also resulted in decreases in whole brain CB1
receptor binding curves compared to vehicle. The non-linear regression of the binding data
revealed a significantly reduced maximal binding (Bmax) by 38% compared to vehicle (Fig 22C
and D). None of the other treatments significantly altered whole brain CB 1 receptor binding
levels. Thus, prolonged complete MAGL inhibition leads to both down-regulation and
desensitization of CB1 receptors in whole brain. Low dose JZL184 alone or in combination with
FAAH inhibition resulted in receptor desensitization in the absence of apparent receptor loss.

82

Table 4. Tetrad effects of MAGL and FAAH inhibitors in ICR mice

Treatment
(mg/kg)

Hypothermia
(ΔoC)

Tail flick latency
(Δ sec)

Catalepsy
(sec)

Time Immobile
(sec)

Vehicle

0.46 ± 0.3

-0.23 ± 0.2

0.00

11.2 ± 1.5

JZL184 (4)

0.19 ± 0.3

0.01 ± 0.1

0.00

9.72 ± 2.9

PF-3845 (10)

0.18 ± 0.2

0.10 ± 0.2

0.00

10.7 ± 1.8

JZL(4) + PF(10) 0.31 ± 0.2

-0.26 ± 0.2

0.00

19.1 ± 7.0

JZL184 (40)

-0.70 ± 0.4

1.19 ± 0.8

0.00

14.6 ± 3.2

THC (10)

-2.02 ± 0.7*

2.21 ± 0.9*

9.05 ± 6

23.6 ± 16

Data represented as mean ± SEM; *p<0.05 v/s vehicle control; n=9/group
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Figure 20: Whole brain levels of endocannabinoids and arachidonic acid in mice with acutely
disrupted MAGL and/or FAAH.
Levels of (A) 2-AG, (B) arachidonic acid, and (C) AEA in the whole brain from mice treated
acutely (single dose i.p. evaluated 2 h later) treated with either vehicle, low-dose JZL184(4
mg/kg), PF-3845 (10 mg/kg), combination of JZL184(4mg/kg) + PF-3845(10mg/kg) and highdose JZL184(40 mg/kg). Data expressed as mean ± SEM. *p<0.05; **p<0.01, ***p<0.001 vs.
vehicle control; n=8 mice/group.
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Figure 21. Whole brain levels endocannabinoids and arachidonic acid from mice repeatedly
treated with MAGL and/or FAAH inhibitors.
Levels of AEA, 2-AG and AA ( treatment: 5 d, one dose per day (i.p.), and evaluated 24 h after
final dose; Panel A-C) and ( treatment: 6 d, one dose per day (i.p.), and evaluated 2 h after final
dose; Panel D-F). Data expressed as mean ± SEM. *p<0.05; **p<0.01, ***p<0.001 vs. vehicle
control; n=6 mice/group.

85

Figure 22. CB1 receptor function in mice following prolonged disruption of MAGL and/or
FAAH.
CP55,940-stimulated [35S]-GTPγS binding as indicated by (A) best fit E max and (B) mean %
stimulation of CP55,940 concentration curve; Membrane-specific CB1 receptor binding by the
1

antagonist [3H]-SR141716A, as evaluated by the (C) best-fit Bmax of binding curves and (D)
specific binding curves, from whole brain homogenates from mice repeatedly treated with
MAGL and/or FAAH inhibitors (treatment: 5 d, one dose per day (i.p.), and evaluated 24 h after
final dose. Data represented as mean ± SEM. *p<0.05; **p<0.01, ***p<0.001 vs. vehicle
control; n=6 mice/group.
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4.7. Discussion
Acutely administered JZL184, which selectively raises brain 2-AG, but not anandamide in
vivo (Long et al., 2009a, Long et al., 2009b), completely blocked all measured behavioral
effects of spontaneous withdrawal, including paw flutters, head shakes, jumps, diarrhea, and
weight loss. The FAAH inhibitor PF-3845 reduced only spontaneous withdrawal-induced paw
flutters and head shakes, but did not attenuate intensity of jumps, diarrhea or body weight loss.
Furthermore, combination of low-dose JZL184 and high dose of the FAAH inhibitor PF-3845
significantly attenuated all measured signs of spontaneous withdrawal. Rimonabant blocked
these effects, indicating a necessary role of CB1 receptors.

The combination elevated

appropriate levels of AEA and 2-AG and did not produce any cannabinoid tetrad effects.
However, repeated treatment of the combination led to CB1 receptor desensitization.
The observation that complete MAGL inhibition significantly blocked all opioid withdrawal
symptoms, while FAAH inhibition only reduced a subset of these effects corroborates with our
previous findings in the precipitated withdrawal model (Ramesh et al., 2011a) (see Chapter 3).
However, the ability of prolonged MAGL inhibition at high doses of JZL184 to elicit
cannabinoid dependence represents a drawback of using these inhibitors in treatment of abuse
disorders (Schlosburg et al., 2010). Alternatively, a combination of low-dose JZL184 (4 mg/kg)
and PF-3845 (10 mg/kg) possessed nearly full efficacy in attenuating physical opiate
withdrawal signs. The magnitude of these effects was comparable to that of complete MAGL
inhibition (40 mg/kg) and augmented in comparison to low-dose JZL184 (4 mg/kg) or PF-3845
(10 mg/kg) alone. The doses of PF-3845 and JZL184 selected for combination were intended to
maximize the therapeutic efficacy of inhibiting both enzymes while avoiding the undesirable
side-effects of complete MAGL inhibition. This combination also produces augmented anti87

allodynic effects in the carrageenan pain assay (Wise, Kinsey et al, unpublished data) and
repeated treatment does not lead to functional CB1 receptor adaptations in C57BL/6J mice.
In these experiments, we stimulated CB1 receptors by elevating endogenous cannabinoid
through the use of inhibitors of their hydrolytic enzymes. We quantified brain levels of
endocannabinoids following acute repeated treatment of JZL184, PF-3845, and combined
JZL184+PF-3845. Notably, the combination of partial MAGL/complete FAAH inhibition
acutely resulted in approximately 2-fold higher levels of 2-AG compared to partial MAGL
inhibition by itself. FAAH blockade by itself did not alter 2-AG levels compared to control
levels.The enhanced elevation produced by the combination may be due to the ability of FAAH
to degrade 2-AG (Blankman et al., 2007). To test this idea, we could examine whether PF-3845
further inhibits 2-AG hydrolysis activity in brain tissue from ICR mice treated with JZL184.
Additionally, it would be necessary to determine if the enhanced elevation is observed in all
relevant brain regions (ex. cerebelleum, LC, nucleus accumbens, striatum, PAG) or restricted to
a specific area.
In a clinical setting, therapeutic agents used to manage of opiate withdrawal would likely be
given repeatedly; therefore, it is important to compare the impact of repeated administration of
compounds on endogenous cannabinoid levels as well as to assess CB1 receptor function.
Repeated administration of 40 mg/kg JZL184 elevated 2-AG whole brain levels 24 h after the
last injection. These results are in agreement with studies in C57BL/6J mice in which repeated
MAGL blockade resulted in up to 12-fold elevations in 2-AG up to 26 h after the last exposure
of JZL184 (Schlosburg et al., 2010). Repeated JZL184 treatment results in more prolonged
inhibition of MAGL and greater 2-AG levels than that produced by an acute injection. The
further increase in 2-AG levels following repeated treatment is probably due to delayed
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recovery of MAGL due to the long half-life of JZL184. Accordingly, repeated administration
of high dose JZL184 also produced significant losses in the maximal stimulation of CB1
receptors in whole brain by the cannabinoid receptor agonist CP55,940. Loss of maximal
activation is usually indicative of desensitization of receptors, in which GRK phosphorylation
and β-arrestin binding prevents typical activation in the presence of ligand. However, given that
the magnitude of loss in receptor activation almost exactly equals the loss of receptor binding
sites in almost all cases, it appears that prolonged 2-AG elevation with high-dose JZL184
promotes significant receptor internalization and degradation. However, repeated treatment with
low-dose JZL184 treatment alone or in combination with PF-3845 did not lead to changes in 2AG levels 24 h post-final injection, suggesting that the levels of 2-AG are normalized over the
course of repeated treatment. We confirmed this observation this observation by also examining
an earlier time point (i.e. 2h) following the final injection of the inhibitors. Accordingly, these
groups showed CB1 receptor desensitization, but no changes in CB1 receptor number in whole
brain. Repeated FAAH inhibition did not lead to accumulation of AEA levels 24h after the last
dose. Thus, FAAH inhibition produces a transient elevation of AEA that does not accumulate in
the brain following repeated treatment. These results confirm previous findings that prolonged
complete MAGL inhibition leads to acculmulation of brain 2-AG and reduction of AA levels
(Schlosburg et al., 2010). Taken together, these findings indicate that the moderate elevations in
2-AG produced by low-dose JZL184, as well as the combination (2-4 fold), induced
desensitization of CB1 receptors, but was insufficient to produce receptor down-regulation.
However, given that cannabinoids induce region-dependent changes in CB1 receptor function
(Breivogel et al., 1999; Schlosburg et al., 2010), regional differences may not be reflected in
whole brain homogenate binding.
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Chapter 5: Anti-diarrheal actions of MAGL inhibition: Effects on naloxone-precipitated
hypermotility and hypersecretion in morphine-dependent ilea
In both the naloxone-precipitated morphine withdrawal and spontaneous morphine
withdrawal models, MAGL inhibition, but not FAAH inhibition, blocked the occurrence of
diarrhea in morphine-dependent mice. The antecedents for diarrhea include increased muscle
contractility and hypersecretion of fluids and electrolytes in the intestinal tract. In this Chapter,
we employed the isolated ileum preparation to investigate the mechanism by which JZL184
blocked diarrhea. Ileum was exposed to morphine for 1 h at which time naloxone was added to
the tissue bath to precipitate contractions and hypersecretion. The ileum offers a useful in vitro
model to investigate opioid withdrawal (Paton, 1957), since it shows tolerance and withdrawal
to prolonged application of morphine. The cannabinoid receptor agonists THC and WIN-55,212
have been shown to reduce naloxone-precipitated contractions in ilea subjected to prolonged
morphine exposure (Frederickson et al., 1976; Basilico et al., 1999).
Intestinal motility is mediated predominantly by longitudinal muscle, which is
innervated by the myenteric plexus, while secretion is controlled by the submucosal plexus
innervating the mucosa and the submucosa (for cross-section of the ileum see Fig. 23). CB1
receptors are believed to be located enteric neurons and extrinsic primary afferent nerves in the
submucosa of ileum. Furthermore, primary afferent nerves that express the CB 1 receptor
predominantly

innervate

regions

of

the

submucosal

ganglia

where

cholinergic

secretomotoneurons are located (MacNaughton et al., 2004). In addition, MAGL mRNA and
protein is expressed abundantly in the submucosal plexus of the rat ileum (Duncan et al., 2008).
MORs are also abundantly expressed in the myenteric and submucosal plexus of the ileum and
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control muscle contractility and secretion/absorption of electrolytes by modulating Ach release
(Paton, 1957; Sheldon et al., 1990; Bagnol et al., 1997). In these experiments, we investigated
whether JZL184 and PF-3845 would ameliorate naloxone-precipitated contractions and
secretion in morphine-exposed ilea.

Figure 23: Cross-section of ileum
Outer-inner layers; Serosa, longitudinal muscle, circular muscle, submucosa amd mucosa.
Muscular layers are innervated by myenteric plexus while submucosa and mucosa receive
innervations from the submucosal plexus. Cannabinoid and opioid receptors are predominantly
located in the neuronal tissue.
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5.1. Methods
Subjects
For EFS studies and studies measuring levels of endogenous ligands, male ICR mice
were used as subjects (Harlan laboratories; Indianapolis). The mice weighed between 26 and 30
g and were housed 4 per cage in a temperature controlled (20-22oC) environment, in an
American Association for the Accreditation of Laboratory Animal Care-approved facility. The
mice were kept on a 12 h light/ dark cycle, with all experiments being performed during the
light cycle. Food and water were available ad libitum. The study was performed with the
approval of the Institutional Animal Care and Use Committee at Virginia Commonwealth
University in accordance with the Guide for the Care and Use of Laboratory Animals.
For Ussing Chamber studies female C57BL/6J as well as female CB1 (-/-) and (+/+)
mice backcrossed onto a C57BL/6J background for at least 13 generations were used as
subjects. The mice weighed between 18-22g and were housed 4 per cage in a temperature
controlled (20-22oC) environment, in an American Association for the Accreditation of
Laboratory Animal Care-approved facility. The mice were kept on a 12 h light/ dark cycle, with
all experiments being performed during the light cycle. Food and water were available ad
libitum. The study was performed with the approval of the Institutional Animal Care and Use
Committee at the University of Maryland at Baltimore in accordance with the Guide for the
Care and Use of Laboratory Animals.
Isometric tension recording
Previously described methods to assess effects of opioids on longitudinal ileal muscle
were employed in the present study (Ross et al., 2008). One-centimeter segments of ilea were
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dissected, flushed of their contents, and trimmed of mesentery.

These preparations were

suspended in the axis of the longitudinal muscle tied to a glass hook under 1 g passive tension in
15 ml of siliconized organ baths containing Krebs solution (118 mM NaCl, 4.6 mM KCl, 1.3
mM NaH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3, 11 mM glucose, and 2.5 mM CaCl2),
maintained at 37°C and bubbled with 95% O2 and 5% CO2. Tissues were allowed to equilibrate
for 60 min before start of experiments, with Krebs solution changed every 15 min. Isometric
contractions were recorded by a force transducer (GR-FT03; Radnoti, Monrovia, CA)
connected to a computer using Acqknowledge 382 software (BIOPAC Systems, Inc., Santa
Barbara, CA). The tissues were incubated with 10µM morphine sulfate for 30 min following a
30 min incubation with either JZL184 (1 µM) or PF-3845 (1 µM). Naloxone hydrochloride (30
µM) was then added to the organ bath to precipitate contractions. Contractions to 80 mM
potassium chloride buffer at the end of the study were used as the reference.
Neurogenic contractions by transmural field stimulation
Electric field stimulation (FS, 20V, 7.5 Hz) was applied through concentric electrodes
over ileal longitudinal muscles. JZL184 (1 µM) or PF-3845 (1 µM) and/or rimonabant (100nM
) was added over FS contractions/ relaxations to determine their effects on the neurogenic
responses.
Measurement of electrogenic ion transport in vitro in Ussing’s chambers.
Small intestinal tissue (including neuromuscular layer; whole SI except the proximal
jejunum) was mounted in Ussing chambers 0.126 cm2 of tissue to 5 ml Krebs buffer containing
10 mM glucose (serosal buffer) and 11.2 mM mannitol (mucosal buffer). The buffer was
maintained at 37oC and continuously aerated 95% oxygen, 5% carbon dioxide. Agar-salt
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bridges and electrodes were used to measure potential difference. Every 50 s, the tissues were
short circuited at 1 V (DVC 1000 voltage clamp; World Precision Instruments, Sarasota, FL),
and the short circuit current (Isc) was continuously monitored.
To test the reactivity/viability of the tissue a high concentration of glucose is applied to
the mucosal level to activate the co-transporter which results in an increased short-circuit
current. Next, the tissue is washed and the glucose and mannitol buffers are applied at the
serosal and mucosal side respectively. Once the short-circuit current (Isc) reaches a stable
baseline, morphine (30µM) is applied to the serosal side. Tissues that do not show an acute
decrease in I sc in response to morphine treatment are not included in the study. After 20
minutes, the buffer is replaced and morphine is applied again. Ten minutes later JZL184
(10 µM) or vehicle (DMSO) is applied to the serosal side. Ten minutes later, the tissue is
washed again and morphine and JZL184/DMSO is immediately re-applied to the tissue. Twenty
minutes later naloxone is applied to the serosal side of the tissue (30µM) to precipitate
withdrawal.
Extraction and quantification of ileum endocannabinoid and prostaglandin levels via LCMS
In this set of experiments, endocannabinoid, arachidonic acid, and prostaglandin levels
were quantified in ileum after either in vivo or in vitro application of JZL184. In the first
experiment, mice were treated with either JZL184 (40 mg/kg) or vehicle and their ilea were
harvested 2 h later. In the second experiment, ilea were harvested and the tissue was allowed to
equilibrate in Krebs buffer for 30 min followed by incubation with either 100nM JZL184 (in
DMSO) or vehicle for 30 min. The tissues were frozen in dry ice and stored at -80o C. Tissues
were weighed and subsequently sheered with a tissue disruptor followed by sonication in 6 ml
of 1:1 v/v hexane:ethyl acetate and 2 ml of Tris buffer (pH 8.0) containing dodecylglycerol (10
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nmol) and pentadecanoic acid (10 nmol) as internal standards for positive and negative mode
ionization, respectively. Samples were centrifuged at 2000 g for 5 min and the organic layer
was removed, dried under a stream of N2, resolubilized in chloroform (120 μl), and 10 μl of this
resolubilized lipid was injected onto an Agilent G6410B QQQ instrument. LC separation was
achieved with a Gemini reverse-phase C18 column (5 μm, 4.6 mm x 50 mm, Phenomonex)
together with a pre-column (C18, 3.5 μm, 2 mm x 20 mm). Mobile phase A was composed of a
95:5 v/v H2O:MeOH, and mobile phase B was composed of a 65:35:5 v/v/v iPrOH:MeOH:H2O. 0.1% ammonium hydroxide was included to assist in ion formation in
negative ionization mode and 0.1 % formic acid was included for positive ionization mode.
The flow rate for each run started at 0.1 ml min–1 with 0% B. At 5 min, the solvent was
immediately changed to 60% B with a flow rate of 0.4 ml min–1 and increased linearly to
100%B over 10 min. This was followed by an isocratic gradient of 100% B for 5 min at 0.5 ml
min–1 before equilibrating for 3 min at 0% B at 0.5 ml min–1 (23 min total per sample). The
following MS parameters were used to measure the indicated metabolites (precursor ion,
product ion,collision energy in V): AEA (348, 62, 11), OEA (326, 62, 11), PEA (300, 62, 11),
2-AG (379, 287, 8), OG (357, 265, 8), PG (331, 239, 8), dodecylglycerol (261, 261, 0),
pentadecanoic acid (241, 241, 0), arachidonic acid (303, 303, 0), PGE2 (351, 271, 10), PGD2
(351, 271, 10), TXB2 (369,195,5), 5,6-EET (319,191,3). MS analysis was performed with an
electrospray ionization (ESI) source. The dwell time for each lipid was set to 60 ms. The
capillary was set to 4 kV, the fragmentor was set to 100 V, and the delta EMV was set to +300.
The drying gas temperature was 350°C, the drying gas flow rate was 11 l min–1, and the
nebulizer pressure was 35 psi. Lipids were quantified by measuring the area under the peak in
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comparison to an external standard curve with MAGs, NAEs, or eicosanoids with the internal
standards.
Statistical Analysis
All data are reported as mean ± SEM. AEA, arachidonic acid, PGE2 and 2-AG levels are
reported as pmol or nmol per gram of tissue, where applicable. Data were analyzed using twoway between measures analysis of variance (ANOVA), followed by Dunnett’s or Scheffe’s post
hoc test. EFS contraction height was compared by paired t-test. Differences of p<0.05 were
considered significant.
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Results
5.1. JZL184 and PF-3845 inhibit naloxone-precipitated isometric muscle contractions in
morphine-dependent mouse ilea
The effects of MAGL and FAAH inhibition were evaluated in an in vitro model of precipitated
withdrawal in which mouse ileal longitudinal muscle is exposed to morphine (10 μM) for 60
min and then naloxone (30 µM) was used to precipitate contractions. The height of naloxoneprecipitated contractions was been normalized to contractions elicited by 80 mM KCl. JZL184
(1 µM) attenuated naloxone-precipitated contractions in morphine-treated tissue [F(2,15) = 6.6;
p <0.01; Fig. 24A]. However, rimonabant (100nM) did not reverse the attenuation of naloxoneinduced contractions by JZL184 (p = 0.73). Representative traces of contraction before and
after application of naloxone in the three conditions are shown in Fig. 24B. In contrast, PF3845 (1 µM) attenuated the intensity of naloxone-precipitated contractions in a CB1 dependent
manner, as indicated by a significant treatment effect [F(2,16) = 12.2; p < 0.001; Fig. 24C; see
Fig. 24D for representative traces of contractions in the three conditions].
5.2. JZL184 but not PF-3845 attenuates neurogenic field-stimulated contractions in naïve
ileal tissue
To investigate further, the impact of MAGL and FAAH inhibition on ileum function, we
evaluated EFS cholinergic contractions in the longitudinal preparations from mouse ileum.
These experiments were carried out in the absence of morphine and naloxone treatment to study
whether the endocannabinoid catabolic enzyme inhibitors directly affected ileal contractility.
The height of contractions was normalized to tissue weight and the height of contractions after
drug treatment was normalized to percentage of pre-drug contraction for each tissue. JZL184
inhibited EFS contractions in the ileum (p<0.05), which was reversed by rimonabant [F(1,8) =
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10.2; p < 0.05, Fig. 25C; Fig 23A for a representative trace]. In contrast, PF-3845 did not
inhibit EFS contractions in the ileum (p = 0.36, Fig. 25C; Fig. 25B for a representative trace).
5.3. Both JZL184 and PF-3845 inhibit naloxone-precipitated hypersecretion in morphinetreated ilea
Since both MAGL and FAAH inhibition reduces naloxone-precipitated hypercontractility, the
effects of MAGL and FAAH inhibition was evaluated in an in vitro model of secretion in ileal
tissue as measured by changes in short-circuit current (Isc). The measured current was
normalized to the surface area of the tissue. Acute morphine treatment by itself caused a mild
decrease in the Isc current. Naloxone exposure (30µM) to both CB1(+/+) and CB1(-/-) ileal tissue
treated with morphine (30μM) for 60 min, resulted in a profound increase in I sc current (p<0.05
v/s morphine control; Fig. 23A). The MAGL inhibitor JZL184 (10μM) and the FAAH inhibitor
PF-3845 blocked naloxone-induced increase in I sc current in wild-type ileum tissue (p<0.05 v/s
morphine-naloxone control; Fig. 26A and 26C). The anti-secretion effects of JZL184 were not
observed in CB1(-/-) tissue (Fig. 26B). Taken together, these data suggest that both MAGL and
FAAH inhibition attenuate naloxone-induced hypersecretion in morphine-dependent ileum
tissue.
5.4. Evaluation of effects of JZL184 on endocannabinoid, arachidonic acid and
prostaglandin levels in ileum
The data depicted in Fig. 24 and Fig. 25 suggest that FAAH inhibition attenuates ileal
contractions during naloxone-precipitated withdrawal in a CB1 dependent manner, but does not
directly affect ileal function in the absence of morphine. However, the finding that rimonabant
did not block the reduction by JZL184 on naloxone precipitated contractions in morphine-
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dependent ilea (Fig. 24A), suggests a non-CB1 receptor mechanism. One mechanism by which
JZL184 may inhibit naloxone-precipitated contractions is by altering arachidonic acid levels
and prostaglandins. It has been previously shown that genetic deletion or pharmacological
inhibition of MAGL leads to a decrease in arachidonic acid levels in brain (Long et al., 2009a;
Schlosburg et al., 2010). Because prostaglandins are a major product of arachidonic acid and
also play a role in modulating neurogenic ileal contractions, we examined whether JZL184
would alter levels of prostaglandin E2 and arachidonic acid as well as levels of AEA and 2-AG
from ileal tissue. Application of JZL184 (1 µM) to ileum in vitro did not significantly alter 2AG, AEA (table 5) or PGE2 (vehicle: 97.1 ± 12.1 pmol/g; JZL184: 99.8 ± 15.1 pmol/g), but
inexplicably increased levels of arachidonic acid (p < 0.05; vehicle: 32.3 ± 3.0 nmol/g; JZL184
66.3 ± 5.3 nmol/g). PF-3845 on the other hand elevated levels of AEA (table 5) but did not alter
levels of 2-AG, AA or prostaglandins (data not shown).
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Figure 24. Inhibitors of endocannabinoid catabolic enzymes reduced naloxone-precipitated
contractions of morphine-treated ilea, as measured by isometric tension recording.

(A) The MAGL inhibitor
JZL184 (1 µM) attenuated
the amplitude of naloxoneprecipitated contraction in
ileum treated with
morphine. Rimonabant
(100nM) did not block the
anti-withdrawal effects of
JZL184. (B)
Representative traces of
contractions in each of the
conditions before and after
application of naloxone
hydrochloride.
(C) The FAAH inhibitor PF-3845 (1 µM) attenuated the amplitude of naloxone-precipitated
contraction. Rimonabant (100nM) reversed the actions of PF-3845. (D) Representative traces of
contractions in each of the conditions before and after application of naloxone hydrochloride.
Data are expressed as mean ± SEM. ***p<0.001, * p<0.05 vs. morphine; ###p<0.001 vs. PF3845; n= 4-8 ilea/condition.
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Figure 25: Evaluation of JZL184 and PF-3845 on field stimulated (EFS) contractions on
longitudinal smooth muscle preparations from naïve ileum

(A) Representative trace of
EFS contractions before and
after addition of JZL184
(1µM). (B) Representative
trace of EFS contractions
before and after addition of
PF-3845 (1µM). (C)
Graphical representation of
the amplitude of contractions
represented as % of baseline
values. JZL184 reduced the
amplitude of EFS-stimulated
contractions though the
activation of CB1 receptors,
but PF-3845 had no effect.
Data expressed as mean ±
SEM. *p<0.05, # p<0.05 vs.
JZL184; n = 4-5 ilea/group.
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Figure 26. Effects of MAGL and FAAH inhibition on naloxone-precipitated hypersecretion in
CB1(+/+) and CB1(-/-) mice.
(A) JZL184 blocks naloxone-precipitated hypersecretion in morphine-treated CB1(+/+) ileum
tissue as measured by change in Isc current normalized to surface area. (B) JZL184 treatment
does not alter naloxone-precipted hypersecretion in CB1(-/-) tissue (C) PF-3845 blocks
naloxone-precipitated hypersecretion in morphine-treated C57BL6/J ileum. Data expressed as
mean ± SEM. *p<0.05 v/s appropriate morphine control; #p<0.05 v/s corresponding morphinenaloxone treated tissue. n=4-5 mice/ group; Data collected by Dr. Terez Shea-Donohue and Dr.
Tim Vanuytsel at the University of Maryland, Baltimore
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Table 5. Effects of FAAH and MAGL inhibitors on AEA and 2-AG levels in the ileum
Data expressed as mean ± SEM. n = 6 mice/group; *p < 0.05 vs. vehicle control.

Treatment

AEA pmol/g

2-AG nmol/g

Vehicle

3.2 ± 0.5

13.2 ± 3.2

PF-3845 (10 mg/kg)

7.9 ± 1.1*

8.8 ± 2.3

JZL184 (40 mg/kg)

6.6 ± 1.6

19.5 ± 4.8
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5.5. Discussion
Based on the differential anti-diarrheal effects between JZL184 and PF-3845, we
predicted a similar association on intestinal motility and secretion in in vitro models of
naloxone-precipitated withdrawal in morphine-treated ilea. To test this hypothesis, we
investigated the effects of endocannabinoid catabolic enzyme inhibitors in in vitro models of
electrogenic mucosal ion transport and neurogenic contractions to account for the anti-diarrheal
effects of MAGL inhibition. JZL184 attenuated the intensity of naloxone-precipitated ileal
contractions, but rimonabant failed to reverse these effects, suggesting that these effects are
non-CB1 mediated. Rimonabant blocked the effects of PF-3845 on naloxone-precipitated
contractions in morphine-dependent ilea. Next, we demonstrated that naloxone can precipitate
hypersecretion of electrolytes in morphine-dependent ileal tissue. In this model, effects of
JZL184 in attenuating naloxone-precipitated hypersecretion in morphine-dependent ilea were
abolished in CB1(-/-) mice suggesting that CB1 receptors modulate the anti-secretory actions of
JZL184.
Cannabinoid receptor agonists have been shown to inhibit the electric field stimulated
(EFS) contractions of myenteric plexus-longitudinal muscle preparations through prejunctional
CB1 receptors. This results in inhibition of contractile activity by blocking the release of
acetylcholine from neurons of the myenteric plexus (Coutts and Pertwee, 1997). Acute exposure
of ileal tissues to morphine also results in inhibition of EFS contractions via inhibition of Ach
release (Paton, 1957). However, prolonged exposure leads to adaptations and naloxone can
precipitate hypercontactility by inducing excess Ach release in these tissues (Tsou et al., 1982).
Given the co-localization of MAGL, FAAH, CB1 receptors and opioid receptors in myenteric
plexus (Bagnol et al., 1997; Coutts et al., 2002; MacNaughton et al., 2004; Bashashati et al.,
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2011), it is possible that both MAGL and FAAH inhibitors indirectly block hypercontractility
during morphine withdrawal by attenuating the release of Ach from myenteric cholinergic
neurons innervating the longitudinal muscle of the ileum.
Acutely, opiates have anti-diarrheal effects by inducing constipation via inhibition of
intestinal motility as well as electrolyte and fluid transport. Opiate withdrawal results in gastrointestinal distress including vomiting and diarrhea. Opiate agonists have been shown to have
anti-secretory activity by affecting ion transport in the small intestine of mice (Sheldon et al.,
1990). Both MOR and DORs have been implicated in the anti-secretory actions of opiates. In
our studies, we have shown that in vitro, these actions of opiates undergo adaptations on
prolonged treatment. This study is first to show that naloxone precipitates a hypersecretory
response in tissues treated with morphine for a prolonged period of time in the Ussing’s
chamber. Cannabinoids also have been shown to have anti-secretory effects. The synthetic
cannabinoid WIN blocks hypersecretion evoked by capsaicin or EFS in in vitro guinea pig and
rat ileum preparations in the Ussing’s chamber in a CB1 dependent manner (Tyler et al., 2000;
MacNaughton et al., 2004). These actions of cannabinoids are mediated by CB1 receptors in the
submucosal plexus of the guinea pig ileum. JZL184 possibly exerts its effects indirectly via CB 1
receptors that are co-localized with MORs in the submucosal neurons (Maguma et al., 2010).
The antecedents for diarrhea include enhanced contractility and increased secretion of
fluids and electrolytes. Two observations from the present study indicate that the in vitro
contraction model does not account for naloxone-precipitated diarrhea in morphine-dependent
mice.

First, both JZL184 and PF-3845 attenuated naloxone-precipitated contractions in

morphine-treated ilea in vitro, but only JZL184 blocked the occurrence of diarrhea in vivo.
Second, rimonabant blocked the anti-diarrheal effects of JZL184 in vivo, but did not reduce
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naloxone-precipitated contractions in ileum in vitro. Thus, while naloxone-precipitated
contractions in morphine-treated ileum reflect a useful in vitro model of opioid withdrawal, this
model does not account mechanistically for the autonomic withdrawal responses (i.e., diarrhea)
observed in vivo. Additionally, both JZL184 and PF-3845 reversed naloxone-precipitated
secretion in ileal tissue from CB1(+/+) and C57BL6/J mice, respectively. JZL184’s antisecretion effects were not observed in CB1(-/-) mice suggesting that CB1 receptors modulate the
actions of MAGL inhibition in this model. The lack of agreement between the effects of these
inhibitors in the in vitro model v/s the differential anti-diarrheal effects observed in vivo may be
due to different antecedents in each of the studies. First, the length of exposure of morphine is
only 1 h compared to 3 days in the behavioral assays. For secretion studies, female C57 mice
served as subjects while in the in vivo studies ICR male mice were used. Finally, in the in vitro
studies, exposure to various drugs was ex vivo in organ baths, while in vivo they were given
systematically.
Curiously, JZL184 did not increase 2-AG levels in ileum. However, the effects of
JZL184 in elevating 2-AG levels are tissue specific. Likewise, JZL184 does not elevate 2-AG
in other peripheral tissues, including testes, white adipose tissue, and lung, though it increases
this endocannabinoid in other tissues, including liver, kidney, brown adipose tissue, and spleen
(Long et al., 2009b). MAGL blockade also reduces free arachidonic acid levels in brain (Long
et al., 2009a), suggesting that the actions of JZL184 could be mediated in part by a blunting in
the production of PGs and other eicosanoids. Additionally, JZL184’s anti-withdrawal effects in
vivo as well as in the in vitro secretion model were reversed by rimonabant and in CB1 (-/-) mice
respectively, implicating the involvement of CB1 receptors. JZL184 did not reduce levels of
PGs in the ileum which corroborates with recent evidence that MAGL inhibition does not alter
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AA and PG levels in gut (Nomura et al., 2011), which further argues against this alternative
mechanism of action. Therefore, it is possible in the present study that increases in 2-AG
occurred in key synapses of enteric neurons obscured by bulk 2-AG in the whole tissue or that
other enzymes regulate 2-AG in ileum, as has been observed for other non-neuronal cells/tissues
(Marrs et al., 2010).
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Chapter 6: Discussion
Summary
Previous studies have examined the ability of THC or exogenous cannabinoid agonists
to reduce somatic opioid withdrawal signs in rodents. The purpose of the studies performed in
this dissertation was to elucidate the potential of elevation of endocannabinoids, via inhibition
of their degradative enzymes, to inhibit opioid withdrawal in pre-clinical rodent models of
dependence. We hypothesized that elevating endogenous cannabinoids following inhibition of
their appropriate catabolic enzymes would inhibit opioid withdrawal, through actions at
cannabinoid receptors. Both MAGL and FAAH inhibition reduced both naloxone-precipitated
as well as spontaneous somatic withdrawal signs with differential efficacy. Given the
undesirable effects of prolonged complete MAGL inhibition and the reduced efficacy of FAAH
inhibition to reduce somatic withdrawal signs compared to MAGL inhibition, we investigated a
combination of partial MAGL and complete FAAH inhibition to maximize efficacy. This
combination also reduced withdrawal signs without any associated dependence liability and
mild receptor desensitization on repeated treatment. Finally, to elucidate the mechanism of antidiarrheal effects, we hypothesized that MAGL but not FAAH inhibition would block
hypercontractility and hypersecretion in the ileum. Both inhibitors blocked hypercontractility
indicating that this model alone does not account for diarrhea. However MAGL inhibition
significantly reduced withdrawal induced hypersecretion suggesting that MAGL inhibitors
block diarrhea via anti-secretory actions.
Differential effects of MAGL v/s FAAH inhibition
Notably, high doses of JZL184 significantly blocked all opioid withdrawal symptoms, while
PF-3845 only reduced a subset of these effects. Several explanations may account for the
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differential effects of these enzyme inhibitors. First, bulk brain levels of 2-AG are at least two
orders of magnitude higher than AEA (Ahn et al., 2009; Long et al., 2009a), which was also the
case in LC, PAG, and amygdala. Thus, elevated 2-AG may achieve greater occupancy of brain
CB1 receptors than AEA. Second, 2-AG acts as a full CB1 receptor agonist, while AEA acts as
a partial CB1 receptor agonist (Sugiura et al., 2002), suggesting that 2-AG produces greater
intrinsic effects at the receptor than AEA. Third, MAGL and FAAH are found in different
neuronal populations and subcellular compartments, which could influence CB 1 receptor
signaling in the brain and result in distinct physiological functions for these endocannabinoids.
For example, 2-AG drives short-term synaptic plasticity, while AEA is quiescent (Pan et al.,
2009). Of course, it is possible that the efficacy of PF-3845 could be enhanced by increasing
the drug pretreatment time or administering multiple injections of this FAAH inhibitor. Thus,
comparison of results with JZL184 and PF-3845 suggests that AEA and 2-AG play different
roles in modulating opiate withdrawal.
Anti-withdrawal mechanism of action of MAGL and FAAH inhibition in vitro
In addition to attenuating somatic withdrawal signs with a higher efficacy, MAGL inhibition
also completely blocked occurrence of diarrhea in vivo, while FAAH inhibition lacked antidiarrheal efficacy. In order to understand the underlying mechanism, we examined the effects of
both MAGL and FAAH inhibitors in in vitro assays of diarrhea. The precursors of diarrhea
include enhanced contractility of the intestinal muscle (i.ie enhanced motility) as well as
hypersecretion of water and electrolytes. Both JZL184 and PF-3845 reduced naloxoneprecipitated contractions and reduced hypersecretion in the ileum in a CB1-dependent manner.
There are several mechanisms by which CB1 activation may modulate anti-secretory effects and
block contractility. One possibility is that activation of CB1 receptors innervating cholinergic
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secretomotoneurons (MacNaughton et al., 2004) may block Ach induced activation of transport
proteins in the mucosa and submucosa (Fig 27). Additionally, CB1 activation in myenteric
neurons may block acetylcholine mediated hypercontraction of longitudinal muscle. Thus,
inhibitors of endocannabinoid catabolic enzymes attenuate opiate withdrawal effects in two
distinct in vitro models in the small intestine.
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Figure 27: Ant-diarrheal mechanism of action of MAGL and FAAH inhibitors in the ileum
(Top) JZL184 and PF-3845 reduces mucosal hypersecretion in the ileum diarrhea through
activation of CB1 receptors in the submucosal neurons (Bottom) Both JZL184 (non-CB1) and
PF-3845 (via CB1) reduce naloxone-precipitated neurogenic contraction of the longitudinal
muscle by affecting Ach release from myenteric neurons.
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Advantages of MAGL and FAAH inhibitors over traditional cannabinoids
While THC and other direct-acting CB1 receptor agonists elicit marijuana-like psychoactive
effects, endocannabinoid catabolic inhibitors appear to possess fewer cannabimimetic effects
than CB1 receptor agonists. In particular, FAAH inhibitors do not substitute for THC in the
drug discrimination paradigm, do not produce hypothermia, hypomotility, catalepsy or memory
impairment, and lack reinforcing properties (Ahn et al., 2008). While the MAGL inhibitor
JZL184 produces a broader set of cannabinoid behavioral effects, including hypomotility,
hypothermia and hyper-reflexia, than FAAH inhibitors, it does not cause the full spectrum of
THC-like effects. In particular, JZL184 does not substitute for THC in the drug discrimination
paradigm and does not produce catalepsy (Long et al., 2009b; Long et al., 2009c). In contrast,
dual inhibitors of both FAAH and MAGL, such as JZL195, produce much greater THC-like
effects, including catalepsy, increased antinociceptive efficacy, and substitution in the THC
discrimination paradigm (Long et al., 2009c) than single enzyme inhibitors, underscoring the
importance of maintaining selectivity for individual endocannabinoid pathways in the
development of FAAH and MAGL inhibitors. Moreover, sustained FAAH blockade does not
alter CB1 receptor function and lacks dependence liability (Schlosburg et al., 2009; Schlosburg
et al., 2010). Additionally, the observation that FAAH (-/-) mice show an attenuated opioid
withdrawal syndrome suggests that the anti-opioid withdrawal effects of FAAH inhibition
persist even upon genetic deletion of FAAH.
Advantages of combining partial MAGL and complete FAAH inhibition
On the other hand, other studies indicate that complete MAGL inhibition may possess
potential for rewarding effects and share other hallmarks in common with drugs of abuse. High
dose JZL184 partially substitutes for THC in the drug discrimination paradigm (Long et al.,
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2009c). In addition, repeated JZL184 elicits cannabinoid dependence, behavioral and functional
tolerance, and cannabinoid receptor cross-tolerance (Long et al., 2009c; Schlosburg et al.,
2010). It should still, however, be noted that many of the cannabimimetic side-effects of
JZL184 are comparatively low in intensity versus moderate to high doses of THC or marijuana.
However, while MAGL inhibitors possess far more side-effects than FAAH inhibitors, they
showed much higher efficacy than FAAH inhibitors in reducing opioid withdrawal symptoms.
Taken together, these results suggest that while both FAAH and MAGL inhibitors individually
represent promising targets for reducing opioid dependence, they also have limitations. In order
to circumvent some of these drawbacks, we investigated whether a combination of partial
MAGL inhibition and complete FAAH inhibition would achieve enhanced efficacy in attenuating

opioid withdrawal signs, without the negative side-effects associated with complete MAGL
inhibition. Partial MAGL inhibition is achieved with lower dose of JZL184 (4 mg/kg) that
produces a physiologically relevant response by elevating 2-AG levels (2-4 fold). The
combination of partial MAGL and complete FAAH inhibition elevates AEA levels similar to
FAAH inhibition alone, but elevated 2-AG levels higher than that observed with MAGL
inhibition alone in ICR mice. Thus, it is possible that the combination exerts beneficial antiwithdrawal effects due to enhanced levels of 2-AG. Although this combination did not produce
CB1 receptor down-regulation, it induced moderate CB1 desensitization following repeated
treatment. In C57BL/6J mice, prolonged exposure to the combination did not induce any CB 1
receptor functional tolerance, analgesic tolerance in pain assays (Wise, Kinsey et al.,
unpublished data) or physical cannabinoid withdrawal. Taken together, the anti-withdrawal and
analgesic effects of this combination coupled with its lack of dependence potential are
important findings for the clinical development of a combined drug that is a partial MAGL and
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a complete FAAH inhibitor. To this effect, a novel inhibitor SA-57 which has differential
potency at MAGL and FAAH has been synthesized (Niphakis et al., 2011). The in vivo
pharmacological actions of this inhibitor remains to be characterized.
Anti-withdrawal mechanism of action: Brain
Although determining the molecular mechanisms for endocannabinoid dampening of
opioid withdrawal is beyond the scope of this dissertation, findings from previously published
reports provide insight. A section of studies has suggested that opioid and cannabinoid receptors
may interact due to their close proximal location within the neuron via signaling with a common
G-protein pool, by forming functional heterodimers, or by allosterically modulating reciprocal
functions (Rios et al., 2006; Hojo et al., 2008; Scavone et al., 2010). It is well established that
acute morphine inhibits adenylyl cyclase at the cellular level, while opiate withdrawal leads to
increased production of adenylyl cyclase and downstream signaling molecules in the LC and
PAG (Nestler and Tallman, 1988; Guitart et al., 1992; Punch et al., 1997). These signaling
events are associated with the expression of somatic and autonomic behavioral withdrawal signs
(Shaw-Lutchman et al., 2002). Thus, increasing endocannabinoid activity may counteract the
consequences of cAMP overshoot during opioid withdrawal (Fig. 28) This notion is consistent
with the colocalization of CB1 and MOR in the LC and other brain regions as well as in the
ileum (Maguma et al., 2010; Scavone et al., 2010). The observations that acute CB1 receptor
stimulation inhibits adenylyl cyclase and decreases cAMP production and that MOR and CB1
receptors have been demonstrated in cell lines to share a common pool of adenylyl cyclase
further supports this hypothesis (Howlett and Mukhopadhyay, 2000; Levitt et al., 2010). The
other less explored hypothesis is that CB1 may modulate signaling of MOR at the extra receptor
level by altering signaling at the second messenger level (cAMP cascade, MAPK cascade or
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Ca2+ signaling); affecting transcription of dependence induced genes or directly modulates
release of neurotransmitters such as dopamine at the interneuronal level. Alternatively, CB1
receptor activation is well known to reduce the release of GABA, glutamate, norepinephrine,
and other neurotransmitters believed to be mediated through the inhibition of the adenylyl
cyclase and the downstream mediators (Piomelli, 2003). Thus, dampening of other transmitters
systems caused by CB1 receptor activation represents an alternative mechanism by which
endogenous cannabinoids could reduce opioid withdrawal.
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Figure 28: Proposed mechanism of action of anti-withdrawal effects of JZL184 in the brain
(Clock-wise) Acute morphine treatment causes suppression of AC activity and its downstream
effects; Chronic morphine exposure leads to upregulation of AC and normalization of
downstream signaling; Induction of withdrawal following chronic morphine exposure causes
cAMP “overshoot” and increasing signaling of cAMP cascade resulting in expression of
withdrawal signs; Acute, indirect CB1 activation by JZL184 inhibits AC and its downstream
cascade, thereby attenuating withdrawal.
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Another important consideration is whether endocannabinoid catabolic enzymes inhibitors
will affect other components of opioid addiction, such as drug reward, extinction, relapse, and
craving. Nonetheless, the results from the present study are the first to show that elevation of
endocannabinoid levels ameliorates the expression of opioid withdrawal. The preliminary in
vitro and in vivo studies presented here establish that endocannabinoid catabolic enzymes may
represent attractive targets to treat severe withdrawal signs associated with opioid dependence.
These inhibitors offer advantages over current treatment options such as benzodiazepines,
methadone, buprenorphine or naltrexone. These inhibitors produce selective elevation of eCBs,
do not substitute for opioids as they do not have the same dependence liability and lack sideeffects of benzodiazepines and opiate substitutes. Additionally, cannabinoids and morphine act
at similar brain regions and affect similar signal transduction pathways. Rather than
management or symptomatic treatment of withdrawal signs, elevating endocannabinoids may
mechanistically alleviate abstinence signs by directly acting on signaling machinery in brain
areas associated with opiate dependence. Thus, the enzymes responsible for endocannabinoid
degradation offer promising targets for possible new treatments for opioid dependence.
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